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Objectives: This study assessed the treatment outcomes of registered tuberculosis (TB) patients 
enrolled in Directly Observed Treatment Short course (DOTS) program at University of Port Harcourt 
Teaching Hospital (UPTH), Port Harcourt, Nigeria between January 2014 and December 2019. The 
study also identified factors associated with treatment outcomes in the cohorts.  
Methods: A retrospective hospital-based cohort study of treatment outcomes of all TB patients 
registered from 1st January 2014 to 31st December 2019 was conducted. Data on treatment outcomes 
(cured, completed, failed, died, lost to follow-up, transferred out, and not evaluated), type of TB 
(pulmonary and extrapulmonary TB), type of patients (new and retreatment cases), HIV status, number 
of patients on anti-retroviral therapy (ART) and co-trimoxazole preventive therapy (CPT), patients’ 
demographic information (age, sex, and weight), diagnostic methods and results were extracted from 
the National TB program (NTP) register and entered in EPIDATA software (v4.6.02) by two 
researchers to ensure that error entries were corrected where possible for consistency and accuracy of 
data. Patients with multi-drug resistant (MDR), and extensively drug resistant (XDR), and patients 
transferred into UPTH with no record of baseline information were excluded from the study. A 
descriptive analysis was performed using the statistical software package (IBM SPSS v25.0), and data 
were categorized, and graphs plotted using Microsoft Excel (v2103.0). At 5% level of significance, 
data comparisons were done using the Chi-square test, and tests for associations between treatment 
outcomes and independent variables were assessed using the bivariate and multivariate logistic 
regression models. 
Results: Of the 816 patients registered for treatment in the hospital, more than half, 443(54.3%) were 
males, and 373(45.7%) were females. Majority of participants 195(23.9%) were in the age group of 0 
– 14 years, and the least participant 76(9.3%) were in ≥55 years age category. The mean age (± standard 
deviation, range) of the patients was approximately 30(±18.8, 1 – 86) years, with median age of 31 
years; and the mean weight (± standard deviation, range) was 43.9(±20.5, 2 – 97)kg with median 
weight of 49kg. Type of TB were 678(83.1%) pulmonary TB, and 113(13.8%) extrapulmonary TB. 
New cases were 736(90.2%) and retreatment cases were 72(8.8%). Out of 305(37.4%) HIV infected 
patients, 291(95.4%) were on ART and 286(93.8%) on CPT. The study found that 226(27.7%) of the 
cohorts were cured, 208(25.5%) completed treatment, 15(1.8%) failed treatment, 110(13.5%) died, 
109(13.4%) lost to follow-up, 90(11.0%) transferred out, and 58(7.1%) were not evaluated. The overall 
treatment success rate (TSR) was 57.3%, and the unsuccessful treatment outcome (UTO) was 42.7%. 
Results of the regression analysis revealed that the risk of treatment success was significantly 
associated with age (0-14 years, OR = 0.4, p = 0.00, 95%CI = 0.2 – 0.6), sex (AOR = 1.4, p = 0.03, 
95%CI = 1.0 – 1.9), pretreatment weight (AOR = 0.4, p = 0.01, 95%CI = 0.2 – 0.8), type of TB (AOR 
= 0.6, p = 0.02, 95%CI = 0.4 – 0.9), HIV status (AOR = 2.0, p = 0.00, 95%CI = 1.5 – 2.8), and 
diagnostic methods (AOR = 0.7, p = 0.03, 95%CI = 0.4 – 0.9).  
Conclusion: The evaluation of treatment outcomes of registered TB patients in UPTH, Nigeria 
between 2014 and 2019 showed a 57.3% overall TSR. This was lower than the 85% national target for 
TB treatment. The study provides evidence that age, sex, HIV, type of TB, pretreatment weight, and 
diagnostic methods associated significantly with TB treatment outcome. There is need to cut TB 
transmission and eliminate the source of infection by treating cases; and detected cases should be 
adequately followed-up. Strengthening National TB control program, and partnership with local 
organizations and communities will help to accelerate the decline in TB mortality and morbidity to 
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1.1 Global Burden of Tuberculosis 
Tuberculosis (TB), a curable infectious mycobacterial disease is one of the top ten global leading 
causes of morbidity and mortality, with an estimated 10 million (range, 8,990000 –11,100000) 
new TB cases worldwide in 2018 (WHO, 2019a).  It remains a major public health threat 
particularly in low- and middle-income countries (LMICs) of the world, where out of thirty high 
TB burden countries in 2018, eight countries accounted for two-thirds of the global TB cases 
(WHO, 2019a). These eight countries and together with twenty-two other countries in the WHO’s 
list of thirty high TB burden countries accounted for 87% of the world’s TB cases.  
Globally, there were about 500 thousand new cases of drug resistant tuberculosis (DR-TB) in 2018, 
of which 78% had multidrug resistant tuberculosis (MDR-TB) (WHO, 2019a). Eighteen percent 
(18%) (range, 7.6 – 31) of estimated global retreatment TB cases and 3.4% (range, 2.5 – 4.4) of 
new TB cases had multidrug rifampicin resistant tuberculosis (MDR/RR-TB) in 2018. The total 
notified global TB cases in 2015 is 6.3 million, and the number that was reported in 2018 is 7.2 
million (WHO, 2019a). This represents 14% (888,922) increase from 2015 total notified cases of 
TB. 
Regionally, according to the 2019 Global Tuberculosis Report (GTR), the least TB cases in 2018 
were in the WHO regions of the Americas (3%) and Europe (3%) and Eastern Mediterranean (8%), 
with higher percentages in the South-East Asia (44%), Africa (24%) and the Western Pacific (18%) 
(WHO, 2019a). The eight countries of the world which accounted for two-thirds of the global TB 
burden were India (27%), China (9%), Indonesia (8%), the Philippines (6%), Pakistan (6%), 
Nigeria (4%), Bangladesh (4%) and South Africa (3%) (WHO, 2019a).  
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However, despite the successes recorded in the world against TB, there are still challenges 
affecting the End TB programme. Laghari et al (2019) have reported missed cases of TB patients 
in large hospitals particularly in tertiary healthcare settings where most of the presumptive TB 
cases go unrecognized, and where the diagnosed and treated cases are not reported to the national 
TB programme or follow national guidelines on TB treatment. Studies have shown that access to 
TB treatment and healthcare services, treatment seeking behavior, adherence to treatment, drug 
resistance status, and knowledge about the disease affect treatment outcomes (Samal, 2016; Ejeta 
et al, 2018; Izudi et al., 2019). Other well-documented studies have observed that the global 
incidence of TB is closely linked with social and economic conditions which makes its prevention, 
care, and management more challenging (Tola et al, 2019), and worsen as a result of multidrug 
resistance, and coinfection with human immunodeficiency virus (HIV) (Ofoegbu and Odume, 
2015; Sakajiki et al. 2018; Abdulkader et al, 2019; WHO, 2019a).  
It is on record that out of the estimated 10 million people that fell ill with TB in 2018, about 1.2 
million (range, 1,160000 – 1,320,000) HIV-negative people died of TB in 2018 (a 21.4% reduction 
from 1.4 million in 2015), and an additional 251,000 TB deaths (range, 224,000 – 280,000) among 
HIV- positive people (a 35.6% reduction from 390,000 in 2015) (WHO, 2019a). Men (aged ≥15 
years) had the highest global burden of TB worldwide and account for 57% of all TB cases in 
2018, whereas women of the same age group and children (aged ≤14 years) account for 32% and 








1.2 Burden of Tuberculosis in Nigeria 
Tuberculosis (TB) is a major public health problem in Nigeria and one of the ten leading causes 
of deaths and hospital admissions in the country (IHME, 2017), as well as the leading causes of 
death among people living with human immunodeficiency virus (PLWHIV) (FMoH, 2010; 
Ofoegbu and Odume, 2015; Odume et al, 2020). The 2019 GTR revealed that Nigeria is ranked 
first and sixth highest TB-burden country in Africa and in the world respectively (WHO, 2019a). 
Nigeria is among the eight countries that accounted for two-third of the global TB burden in 2018 
(WHO, 2019a), with a total of 429,000 (range, 280,000 - 609,000) estimated TB incidence (Figure 
1, presented per 100,000 of  population), representing 26.3% increase (110,000) from 2017 total 
TB incidence which was estimated at 418,000 (range, 273,000 - 594,000), and 26.8% (157,000) 
reduction from 2015 estimated 586,000 (range, 345,000 – 890,000) TB incidence cases (WHO, 
2016a). There was an estimated 125,000 (range, 73,000 – 192,000) TB deaths among HIV-
negative people in 2018 (a 30.6% reduction from 180,000 in 2015), and an additional 32,000 TB 
deaths (range, 20, 000 – 47 000) among HIV- positive people (a 43.9% reduction from 57,000 in 
2015) (WHO, 2016a, 2019) (Figure 2, presented per 100,000 of population).  
Out of about 182 million people in Nigeria in 2015, there were an estimated 586,000 incident cases 
of TB among males and females, of which 322,000 (range, 210,000 – 434,000) were adult males 
and 198,000 (range, 67,000 – 328,000) were adults females (aged >14 years), and 34,000 (range, 
20,000 – 47,000) and 33,000 (range, 14,000 – 52,000) were male and female children (aged 0 – 
14 years) respectively (WHO, 2016a). In 2018, the highest estimated burden is in men (aged ≥15 
years), who accounted for 58% of all TB cases (WHO, 2019a). By comparison, women accounted 
for 34% and children (aged <15 years) for 8%. Reason for male preponderance may be due to 
more exposure to risk factors for TB than females, underutilization of the DOTS services by 
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females, and could be as a result of socio-cultural factors in the area that expose male to 
overcrowding which could lead them to becoming infected (Neyrolles and Quintana-murci, 2009; 
Gebrezgabiher et al, 2016; Sakajiki et al, 2018). In children, TB is still underdiagnosed and 
underreported (WHO, 2019a), and screening children cohabiting with TB infected adults therefore 
becomes necessary to improve the TB detection rates among children (Sakajiki et al, 2018).  
In 2018, there were about 21,000 (range, 13,000 – 32,000) estimated incidence of MDR/RR-TB 
in Nigeria, of which 4.3% (range, 3.2 – 5.5) are new cases and 15% are retreatment cases (range, 
11 – 19) (WHO, 2019a). Out of this estimate, only 1900 patients received treatment (WHO, 
2019a). It is believed that the total number of new and retreatment cases of TB and MDR/RR-TB 
cases in Nigeria, a country with a population of about 200 million people, with myriads of patient-
centered and healthcare-system related factors, are either underreported or underdiagnosed 
(Murray et al, 2015; Adejumo et al, 2017; Beatrice et al, 2017; Bieh et al, 2017; WHO, 2019a). 
Consequently, there are relatively high treatment failure rates amongst retreatment cases (Atif et 
al, 2018), high lost to follow-up of TB patients, and high mortality rates in Nigeria (Oyefabi et al, 
2017; WHO, 2019a). Figure 3 shows the map of Nigeria. 
The National Tuberculosis and Leprosy Control Programme (NTBLCP), an establishment under 
the Nigeria’s Federal Ministry of Health (FMoH), that is saddled with the responsibility of 
reducing TB prevalence by 50% and mortality by 75% by 2025 have been on-top of the situation 
through its national strategic plan of 2015 – 2020 with the hope to save lives and reach zero TB 
deaths, as well as reduce the burden and impact of the disease, DR-TB and comorbidities (FMoH, 
2014). The agency estimated that 4,097,114 cases of TB will occur in Nigeria between the 
beginning of 2015 and the end of 2020 (FMoH, 2014). Of these, approximately 901,365 will be 
co-infected with HIV and 196,661 will have MDR-TB based on the TB prevalence survey report 
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and the TB drug resistance survey data (FMoH, 2014). In 2018, over half of this estimated TB 
incidences and deaths have been reported (WHO, 2019a). The implication of this report is that the 
figures presented by NTBLCP may be impossible as current situation showed that the estimated 
TB figure may have surpassed by 2020. Notwithstanding, finding missed cases, early diagnosis 
and successful treatment of TB patients can help to reduce the incidences and mortality rates of 
TB by ensuring that infected persons are identified on time, placed on anti-TB treatment, and 
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HIV - TB deaths 97 99 62 63 64
HIV+ TB deaths 44 31 21 18 16
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Figure 1: Total estimated TB incidence rate per 100,000 population in Nigeria (2014 – 2018). 
 
Figure 2: Trends in the estimated number of deaths caused by TB and HIV coinfection, and the 









1.3.1 What is Tuberculosis? 
Tuberculosis (TB), according to American Lung Association (ALA), is an infectious disease that 
usually attacks the lungs but can affect almost any part of the body (ALA, 2020). The chronic 
airborne infectious disease (TB) has affected human hosts for thousands of years (Donoghue et al, 
2004; Chisholm and Tanaka, 2016). It is caused by the microorganism, Mycobacterium, a tubercle 
bacillus (Koch, 1882; Sakula, 1982). There are different species of the mycobacteria namely: M. 
tuberculosis, M. bovis, M. africanum, M. microti, M. pinnipedii, M. orygis, M. mungii, M. caprae, 
and M. canetti (van Soolingen, 1997; Pfyffer et al, 1998; Gordon and Parish, 2018). Following the 





prove of TB transmissibility and infectiousness by the French physician, Dr Jean-Antoine Villemin 
in the 1860s (Villemin, 1868), the tubercle bacillus was discovered by the German physician and 
microbiologist, Robert Koch in 1882 (Sakula, 1982; Barberis et al, 2017). Koch’s discovery of the 
bacteria then had little immediate influence on the decline in tuberculosis mortality rates that was 
underway (Murray et al, 2015). As more things were learnt about the disease, the sanatorium 
movement, led by Hermann Brehmer, began to have a major influence on the care that patients 
with all forms of TB received (Daniel, 2011; Murray et al, 2015). 
The M. tuberculosis is the most common causative agent of the disease (Cambier et al 2014), and 
it can persist in populations with the ability to survive, infect or hide for many years, about 10 to 
30 years (Hunter, 2011). There are two clinical manifestations of the disease: active and latent 
(non-apparent) disease (Flores-Valdez, 2017). Tuberculosis infection can evolve from 
containment in the host, in which the bacteria are isolated within granulomas (latent TB infection), 
to a contagious state (active TB infection) (Pai et al, 2016). Only active pulmonary TB is 
contagious (Pai et al, 2016). And about 5-10% of the infected persons may develop the disease 
(CDC, 2014a; Dutta and Karakousis, 2014; Bloom et al, 2017; WHO, 2018; Jilani et al 2020). 
1.3.2 Transmission and Pathogenesis of Tuberculosis 
The mode of transmission of TB is by inhalation of airborne droplet nuclei of bacilli expelled by 
the person with active pulmonary TB (Figure 4), (CDC, 2014b; Chakaya et al, 2016; WHO, 
2016a). When a susceptible recipient is exposed to the tubercle bacilli, infection is established. 
The infection pathway involves the mycobacteria passing through the airways and get deposited 
in the alveoli of the lungs (Gideon and Flynn, 2011; Torrelles and Schlesinger, 2017). Pulmonary 
alveolar macrophage starts to initiate activation of immune cascades that can either result in the 
elimination of the bacilli or lead to the development of TB disease (de Martino et al, 2019). This 
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follows the natural course of TB, starting from (a) the host immune response – which is strong 
and capable to kill the bacteria. When the macrophages kill the bacteria, the host has low 
probability to experience TB in the future, but when the causative agent conquers the host’s 
macrophages, it forms a complex or lesion in the lung known as granuloma (Schluger, 2005). 
Once the granuloma becomes large enough, it forms a Gohn focus (Reece et al, 2010; Thwaites, 
2014; Delgado and Bajaj, 2020). If the infection is not controlled at this local site, there is a spill-
over of the infection to the regional lymph nodes in the lungs forming a Gohn complex (comprising 
of the regional lymph nodes and the Gohn focus) (Hunter, 2011) (b) Primary infection – bacteria 
start to grow and multiply, leading to the clinical stage (Primary tuberculosis) of the disease 
(Mustafa, 2000). The bacteria produce a cavity in the lung. About 90% of primary infections do 
not progress to disease (Schluger, 2005; Heemskerk et al, 2015). The infected person may be 
healed, or the bacteria will (c) remain ‘silent’ and asymptomatic (Latent infection) – the bacilli 
is dormant, which means it cannot cause disease (Flores-Valdez, 2017). Studies have shown that 
about 90-95% of cases end at the latent stage and mostly do not develop TB disease, while the 
remaining 5-10% may be reactivated and enter (d) Post-primary TB - which is a clinical stage of 
disease development, when the dormant bacilli become active and get a chance to multiply and 
grow (Gideon and Flynn, 2011; CDC, 2016a; Jilani et al, 2020). New TB exposure (re-infection); 
co-morbidities especially HIV and diabetes; organ transplants; compromised host immunity; 
alcohol misuse and intravenous abuse of drugs; malnourishment and smoking can cause 
reactivation of latent TB (Hunter, 2018; MacPherson et al, 2020). (e) Disseminated TB (Miliary 
TB and meningitis) – primary TB can further lead to local progression of Gohn focus and 
dissemination of infection in the lungs and to other organs and all parts of the body (e.g. lymph 
nodes, brains, kidneys, liver and spleen), where they can go into latent phase and wake up later as 
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post-primary in the body (Hunter, 2011; Muller, 2016). Miliary TB often includes meningitis. It 
has a peculiar feature of tiny spots like ‘millet seeds’ all over the organs (CDC, 2014b; Jilani et al, 
2020). It is most common in children under 5 years of age, and in severely immuno-compromised 
persons (CDC, 2014b). Tuberculous meningitis results when TB occurs in the tissue surrounding 
the brain or spinal cord. Up to about 25% of patients with miliary TB may have meningeal 
















                       Figure 4: Transmission of tuberculosis 













1.3.3 Disease Site 
Tuberculosis patients are registered as either pulmonary or extrapulmonary, due to different 
contagiousness.    
a). Pulmonary TB (PTB): This is the most common form of TB that is clinically diagnosed or 
bacteriologically confirmed involving lesions in the pulmonary parenchyma (lungs) or the 
tracheobronchial tree (Laghari et al, 2019). It represents about 60 – 80% of all clinical diseases 
attributed to TB worldwide (Ait-khaled et al, 2010). Pulmonary TB is contagious and can either 
result from either primary or secondary TB (Jilani et al, 2020). Typically, the lower lobes of the 
lungs are associated with primary TB while the upper lobes, secondary TB (Geng et al, 2005).  
b). Extrapulmonary TB (EPTB): This occurs when mycobacteria affect other organs other than 
the pulmonary parenchyma (WHO, 2009). Lesions are found elsewhere but not in the lung 
parenchyma (Ramirez-Lapausa, 2015). It may be found in organs of the body such as lymph nodes, 
bones/joints, central nervous system (CNS), skin, pleura, abdomen, breast, heart (pericardium), 
and general urinary tract (Ait-khaled et al, 2010; WHO, 2013; Laghari et al, 2019). It is sometimes 
life threatening such as in TB meningitis and TB pericarditis while others can cause significant 
disability and ill-health (Alex-Hart and Paul, 2019). Extrapulmonary TB is usually less fatal than 
PTB. It accounts for about 15 - 25% of all TB cases with an increasing global annual incidence 






1.3.4 Signs and Symptoms of Tuberculosis 
The commonest signs and symptoms of PTB include cough (coughing up sputum), fever, fatigue 
chest pain, malaise, night sweats, dyspnea/SOB (inability to breath well), loss of appetite, weight 
loss, and hemoptysis (CDC, 2016b). If TB disease is in other parts of the body (extrapulmonary), 
symptoms will depend on the area affected (CDC, 2016c). 
1.3.5. Methods of Tuberculosis Diagnosis 
Treatment and control of TB requires a quality assured diagnosis of patients. According to the 
WHO information note on TB diagnostics and laboratory services, successful directly observed 
therapy strategy (DOTS) expansion, and programmatic management of drug-resistant and HIV-
associated TB require a robust network of TB laboratories with adequate biosafety, modern 
methods for diagnosis, standard operating procedures, and appropriate quality assurance (WHO, 
2020a).  There are so many methods of TB diagnosis, these include: 
Tuberculin skin test (TST) (e.g. Mantoux test) and Interferon-gamma-release-assay (IGRA) 
(e.g. QuantiFERON TB Gold Plus® and T-SPOT TB®). These are used to test for M. 
tuberculosis infection. The TST is carried out by injecting a small amount of fluid called tuberculin 
into the skin of the patient in the lower part of the arm (ATS, 2000; Kroon et al, 2020). Tuberculin 
skin test requires two times visits by a patient, the test is read within 48 to 72 hours by a trained 
healthcare worker (WHO, 2011a), who looks for a reaction (induration) on the arm. Whereas the 
IGRA measures the patient’s immune system reaction to M. tuberculosis in a whole blood sample. 
The IGRA is specific on mycobacteria while the TST is not specific (Leyten et al, 2007; PHO, 
2019). The TST is a sensitive method to detect TB infection (Leyten et al, 2007). The disadvantage 
of TST is that previous BCG vaccine and nontuberculous mycobacteria can provide 
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immunological response and give “false positive” results (ECDC, 2011). Unlike the TST, the 
IGRA results may be ready in 24 hours and is not affected by either the BCG vaccine or the booster 
effect (ECDC, 2011). In case of negative IGRA, the test is repeated 8–10 weeks after the last 
exposure to an infectious TB case. The IGRA should also be chosen as the first method for 
examining groups such as health professionals and other groups that are extensively BCG-
vaccinated, and who have often had repeated TST over time (ECDC, 2011). The IGRA and the 
TST cannot accurately predict the risk of infected individuals developing active TB disease, and 
neither IGRA nor the TST should be used for the diagnosis of active TB disease (WHO, 2011a). 
Chest X-ray (radiography) can help to localize abnormalities such as cavities and lesions in the 
lung, but further examination is required to confirm the cause of the abnormality, and only 
bacteriology can provide proof of M. tuberculosis infection (Bhalla et al, 2015). Chest X-ray can 
help to rule out active TB disease. It is still widely believed that PTB can be diagnosed by chest 
radiography alone (Koppaka and Bock, 2004). However, studies have shown that no radiographic 
pattern is diagnostic of TB (Koppaka and Bock, 2004). Many diseases of the lung show a similar 
radiographic appearance and can easily be mistaken for TB (Koppaka and Bock, 2004). 
Sputum smear examination via microscopy is an important method used to diagnose the most 
infectious cases and treating these cases will have an immediate impact on reducing the 
transmission of TB (WHO, 2015). More than 90% of infectious patients develop perceptible 
symptoms within a few weeks of the onset of TB (Toman, 2004), early detection of TB is possible 
by sputum examination of symptomatic persons – not by traditional mass radiography (Toman, 
2004). Mass radiography would detect most of these cases only 1–3 years after the onset of the 
disease, by which time most of the harm had already been done to the host (Toman, 1974; Toman, 
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2004). Sputum smear microscopy is fast and inexpensive method for acid fast bacilli 
(Mycobacterium tuberculosis) detection in high incidence areas but has low sensitivity (Uddin et 
al, 2013). 
The use of conventional culture as a routine diagnostic and follow-up test is regarded as the gold-
standard for the diagnosis of TB (Saktiawati et al 2019a, 2019b). This diagnostic method is able 
to detect viable M. tuberculosis. Culture allows testing for antibiotic resistance, and it is required 
to monitor treatment response (culture conversion) of drug resistant patients (WHO, 2014a). It is 
relatively sensitive than smear microscopy (Olaru et al 2014; WHO, 2008a; ECDC, 2018). The 
disadvantages of culture technique includes that it is a slow process, and may take up to 6 – 8 
weeks to get a culture result or bacillus visible colonies; the use of costly semi-automated and 
automated systems with liquid media to shorten culture time to less than 2 weeks is glaring; longer 
time for culture may result in delay treatment; expensive for PTB diagnosis; not feasible to perform 
culture in routine for monitoring treatment response in the low resource high TB endemic setting; 
laborious and involves media preparation; and expectorates may contain M. tuberculosis and other 
bacterial contaminants, and consequently the sputum samples or smears requires 
decontamination/optimization before use (den Hertog et al, 2010; ECDC, 2018; WHO, 2020a).  
Molecular methods of diagnosis such as polymerase chain reaction tests (PCR), and Xpert 
MTB/RIF are methods for TB diagnosis. The PCR is very expensive and complicated (Knight et 
al, 2018). It’s highly sensitive and specific to mycobacteria (Lee et al, 2011; Reed et al 2016; 
Vinuesa et al, 2018), and can identify specific TB strains. Xpert MTB/RIF detects both TB and 
rifampicin resistance in a single test (WHO, 2011b, 2011c). Rifampicin resistance is a good and 
reliably proxy for MDR-TB in high burden setting (Jørstad et al, 2018).  Hence, the molecular 
method is used as a stand-alone diagnostic test in individuals at risk of MDR-TB. It is simple and 
14 
 
robust enough to be introduced outside conventional laboratory settings (WHO, 2014b). The assay 
provides results directly in less than 2 hours (WHO, 2014b). It is highly specific, with higher 
sensitivities close to that of culture: 98 – 100% of sputum smear-positive, and 57 – 83% of smear-
negative (Jørstad et al, 2018). The system is closed and there is no contamination (Dorman et al, 
2012). The WHO recommends using it as the initial diagnostic test instead of conventional 
microscopy, culture and drug susceptibility testing (DST) in individuals suspected of MDR-TB or 
HIV-associated TB (WHO, 2014b). However, Xpert MTB/RIF method does not eliminate the need 
for conventional microscopy culture and DST which are required to monitor treatment progress 
and to detect resistance to drugs (WHO, 2016b). Unlike culture method, Xpert MTB/RIF does not 
monitor sterilization during treatment. It cannot differentiate between viable and dead M. 
tuberculosis, hence cannot be used to monitor treatment success or failure, or relapse (Lawn et al, 
2013). Also, it cannot differentiate between M. tuberculosis, M. bovis, and BCG vaccine (Young, 
2017). False-positive rifampicin resistance is possible (van Rie et al, 2012; Cayci et al, 2017; 
Ngabonziza et al, 2020). It is expensive, and a sophisticated hardware which requires calibration, 
maintenance, and linkage to a computer system (WHO, 2011c; Lawn et al, 2013). Operators need 
training in basic computer applications (WHO, 2008b). In addition, it requires continuous 
electrical power supply and air conditioning, thus this may pose a challenge in a low-resource 
setting (e.g., poor rural communities) where there are lack or poor supply of electricity (WHO, 
2008b). Use of generators to generate electricity as a panacea to solve challenge of electricity may 











1.3.6 Tuberculosis Treatment and Control 
The TB control strategy, “the DOTS strategy” was developed by Dr. Karel Styblo, the father of 
modern TB control, to stop TB epidemics (Migliori et al, 2011). Basically, the aim of the strategy 
is to identify the sources of TB and cure them. It involves looking out for the most infectious cases 
(i.e. the sputum smear positive pulmonary tuberculosis patients) and treating them with the 
required standard regimen (if they are new cases): isoniazid, rifampicin, pyrazinamide and 
ethambutol (intensive phase) for 2 months to quickly kill the rapidly dividing bacilli, control 
disease, render patients non-infectious and prevent emergence of drug resistance; and thereafter 
treating with isoniazid and rifampicin (continuation phase) for 4 months to sterilize by killing 
dormant and semi-dormant bacilli, and to prevent relapse (WHO, 2014a). The directly observed 
therapy strategy (DOTS) is the most effective strategy to ensure adherence to TB treatment (CDC, 
2016d). It has been revealed that the strategy leads to improved treatment outcome with overall 
reduction in morbidity and development of MDR-TB (Sakajiki et al, 2018).  
 
1.3.6.1 Principles of DOTS Strategy 
There are five basic principles of DOTS strategy: 
a). Political commitment with increased and sustained financing: this provides the overall 
stewardship to keep TB elimination high on the developmental agenda through political 
commitment, investments, and oversight, while making rapid progress towards social protection 
and universal health coverage. 
b). Diagnosis: case detection focused on quality-assured sputum microscopy/bacteriology or any 




c) Standard directly observed treatment “DOT”: standardized treatment, with supervision and 
patient support. 
d). Regular uninterrupted drug supplies and management system.  
e). Monitoring, recording, evaluation, and reporting.  
In addition, the End TB strategy global plan which builds on the DOTS strategy have three pillars 
and components which stakeholders must apply, and they are the fulcrum to eradicating TB and 
achieving sustainable development goal 3.3 target (ending the epidemic of AIDS, TB, malaria, and 
other neglected tropical diseases) by 2030 (Table 1).  These three pillars according to WHO 
(2014c) are:   
i. Integrated, patient-centered care and prevention - early diagnosis of TB including 
universal drug; susceptibility testing, and systematic screening of contacts and high-
risk groups; treatment of all people with TB including drug-resistant TB, and patient 
support; collaborative TB/HIV activities, and management of co-morbidities; and 
preventive treatment of persons at high risk, and vaccination against TB. Vaccination 
of children with the Bacille Calmette-Guérin (BCG) vaccine confers protection, 
especially from severe forms of TB in children. 
ii. Bold policies and supportive systems - political commitment with adequate resources 
for TB care and prevention; engagement of communities, civil society organizations, 
and public and private care providers; universal health coverage policy, and regulatory 
frameworks for case notification, vital registration, quality and rational use of 
medicines, and infection control; social protection, poverty alleviation and actions on 
other determinants of TB.  
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iii. Intensified research and innovation - discovery, development and rapid uptake of new 
tools, interventions, and strategies; and research to optimize implementation and 
impact and promote innovations. 
Table 1: The End TB strategy  
Indicators Milestones Targets 
 2020 2025 SDG 2030 End TB 2035 
% Reduction in the absolute number of TB 
deaths 
35% 75% 90% 95% 
% Reduction in the TB incidence rate 20% 50% 80% 90% 
% of TB-affected households experiencing 
catastrophic costs due to TB 
0% 0% 0% 0% 
% Treatment success rate ≥90% ≥90% ≥90% ≥90% 
Source: WHO, 2019a 
 
1.4 Nigeria Tuberculosis Control Programme (NTBLCP) 
The National Tuberculosis, Leprosy and Buruli Ulcer Control Programme (NTBLCP) was 
established in 1989 by the government of Nigeria to coordinate and ensure the successful control 
of TB and leprosy (TBL) in Nigeria. This mandate was expanded in 2006 to include the control of 
buruli ulcer. The NTBLCP started the implementation of DOTS strategy through public health 
facilities in 1993 (Adejumo et al, 2020). In 2014, it launched a six-year National Strategic Plan 
(NSP) for TB (2015 - 2020) which operated along the three tiers of Nigerian government (Federal, 
State and Local Government Area). At the Local Government Area, State, and Federal levels, TB 
control activities are coordinated by a Local Government TBL Supervisor (LGTBLS), State TBL 
Control Officer (STBLCO), and National Coordinator (NC) respectively. The LGTBLS is 
responsible to the Head of Department at the Local Government Area headquarters. The LGTBLS 
oversees the activities of the DOTS providers within their area and send quarterly reports to the 
STBLCO. The STBLCO also provides secondary and technical assistance to the Local 
Government level as well as report to the NC. Also. The STBLCO is administratively responsible 
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to the Director of Public Health at the State Ministry of Health. While NC is responsible for the 
entire TB programme in Nigeria. The office provides managerial and technical support to the 
STBLCOs and Zonal TBL control programme coordinators, and reports to the Director of Public 
Health at the Federal Ministry of Health, Nigeria. 
1.5 Rationale of the Study 
In Nigeria, ending TB epidemics is a serious challenge to the government and its health sector. 
Despite its efforts, a significant number of people infected with TB are unknown to the health 
system or are not receiving proper treatment (Abdulkader et al, 2019). High rates of lost to follow-
up of TB patients placed on treatment undermines successful management and treatment of TB 
(Oyediran, 2019). Patients who break the continuity of treatment are more likely to relapse with 
TB, and if they do not adhere to treatment are at risk for developing DR-TB (Alipanah et al, 2018). 
This poses a serious threat to the achievement of 85% treatment success which is the national target 
for TB treatment, as well as affect the achievement of 90% TB incidence reduction and end 90% 
of TB deaths by 2035. Retrospective cohort findings have established that the treatment outcomes 
for TB in Nigeria are below this 90% WHO benchmark for all persons diagnosed with TB and 
initiated on TB treatment services (Joseph et al, 2015; Ogbudebe et al, 2016; Adejumo et al, 2017; 
Sakajiki et al. 2018). According to Oyefabi et al (2017), both the low TB case detection and poor 
treatment outcomes are serious challenges militating against the End TB programme in Nigeria. 
The issue of the treatment outcome for TB has, therefore, become very important due to increasing 
TB prevalence, coinfection with HIV, its close association with poverty, and the growing 
prevalence of DR-TB (Oyefabi et al, 2017). Evaluation of treatment outcomes at University of 
Port Harcourt Teaching Hospital (UPTH) – Rivers State, Nigeria between January 2015 and 
December 2018 showed poor TB treatment outcomes in terms of cure and mortality rates in 
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patients infected with TB (Alex-Hart and Paul, 2019). However, this study excluded patients aged 
more than 18 years. Therefore, assessing the treatment outcomes of all registered TB patients in 
the hospital is imperative since it will improve the performance of national TB control programs 
(NTBLCP) and reduce TB morbidity, and mortality, and reduce the increasing number of MDR-
TB in UPTH (Iwunze et al, 2017), as well as reduce the rate of death among PLWHIV (Ofoegbu 
and Odume, 2015). In addition, further information is required on the outcomes of TB treatment 
in all forms of TB and all age groups and on the trend of the outcome in UPTH. Hence, this study 
assessed treatment outcomes of all registered types and forms of TB patients enrolled in DOTS 
















2. Aim and Objectives of the Study  
2.1 Aim of the Study  
The aim of this study is to assess treatment outcomes of registered TB patients enrolled in directly 
observed treatment short course (DOTS) programme during January 2014 – December 2019 in 
UPTH, Nigeria.  
2.2 Objectives of the Study  
i.          To determine the trends of treatment outcomes in all forms of registered TB patients 
 enrolled in DOTS during January 2014 – December 2019 in UPTH, Nigeria.  
ii.        To identify the factors associated with treatment outcomes in all forms of registered 











3. Materials and Methods  
3.1. Operational Definitions 
 a). Tuberculosis: This is a chronic airborne infectious disease which has affected humans for a 
thousand of years (WHO, 2013); and according to International Union Against Tuberculosis and 
Lung Disease (IUATLD), it is caused by Mycobacterium tuberculosis (Aït-Khaled et al, 2010).  
b). Pulmonary TB (PTB): This the most common type of TB that is clinically diagnosed or 
bacteriologically confirmed involving lesions in the lung parenchyma or the tracheobronchial tree 
(FMoH, 2010; WHO, 2013).  
c). Extrapulmonary TB (EPTB): EPTB is a form of TB that affects other organs other than the 
lungs (FMoH, 2010; WHO, 2013)), with lesions that are found elsewhere (e.g. organs of the body 
such as lymph nodes, bones/joints, central nervous system, skin, pleura, abdomen, breast, heart or 
pericardium, and general urinary tract) but not in the lung parenchyma (WHO, 2013). 
d). HIV-positive TB patient: This refers to any case of TB who has a positive result from HIV 
testing conducted at the time of TB diagnosis or other documented evidence of enrolment in HIV 
care, such as enrolment in the pre-ART register or in the ART register (WHO, 2013).  
e). HIV-negative TB patient: This refers to any bacteriologically confirmed or clinically 
diagnosed case of TB who has a negative result from HIV testing conducted at the time of TB 
diagnosis (WHO, 2013). 
f). Bacteriologically positive patient: A registered patient whose biological specimen is positive 
by smear microscopy, culture, or WHO-approved rapid diagnostics (such as Xpert MTB/RIF). For 
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the microscopy, at least sputum specimen(s) must be positive for acid-fast bacilli (AFB) (WHO, 
2013).  
g). Bacteriologically negative patient: A registered patient whose biological specimen is negative 
by smear microscopy, culture or WHO-approved rapid diagnostics (such as Xpert MTB/RIF) 
(WHO, 2013). 
h). Types of patients: This refers to new, and retreatment (with relapse, return after lost to 
followup, return after failure, others) cases.  
i.          New case: A registered TB patient without or with less than one month of previous   
 treatment (WHO, 2013, 2014c).  
ii.        Retreatment case: According to WHO (2013) definition, this includes: 
- Relapse patient: A bacteriologically confirmed positive registered TB patient who was 
previously treated and declared cured, or treatment completed at the end of their most recent course 
of anti-TB treatment and are now diagnosed with a recurrent episode of TB (either a true relapse 
or a new episode of TB caused by reinfection).  
- Treatment after failure patient: A bacteriologically confirmed positive registered TB patient who 
have previously been treated for TB and whose treatment failed at the end of their most recent 
course of treatment.  
- Treatment after loss to follow-up (default) patient: A bacteriologically confirmed positive 
registered TB patient who have previously been treated for TB and was declared lost to follow-up 
at the end of their most recent course of treatment.  
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- Other previously treated patients: they are those who have previously been treated for TB, and 
get TB again, but not sputum confirmed, e.g., EPTB or smear negative PTB. 
i). - Transferred in: A registered patient who has been transferred from another unit or hospital 
and whose baseline data were not available in the TB register.  
j). Treatment outcome: The components of treatment outcomes were defined according to WHO 
(2014a, 2014b, 2015). 
i. Cured: A registered patient who was smear or culture positive at diagnosis, but on 
treatment completion, show smear or culture negative in the last month of treatment 
and at least one previous occasion during treatment. 
ii. Treatment completed: A registered TB patient who completed treatment without 
bacteriological evidence of failure or cure, either because tests were not done or 
because results are unavailable. 
iii. Treatment failure: A registered TB patient who remained sputum smear or culture 
positive at 5th month or later during treatment. (i.e., patients remain smear-positive at 
five months despite correct intake of anti-TB medication).  
iv. Died: They are registered TB patient who died for any reason before starting or during 
the course of treatment. 
v. Loss to follow-up (defaulter): A registered patient whose treatment was interrupted 
for two consecutive months or more.  
vi. Transferred out: A registered patient who has been transferred to another treatment 




vii. Not evaluated: Refers to group with missing information whom no treatment outcome 
is assigned. This includes cases ‘transferred out’ to another treatment center as well as 
cases for whom the treatment outcome is unknown to the reporting unit. 
 k). Treatment success (successful outcome): This is defined as the total number of all registered 
patients that were cured and all those whose treatment were completed (i.e., cured + treatment 
completed). 
l). Unsuccessful treatment outcome: This is defined as the sum of all registered patients who are 
not successfully treated (i.e., failed treatment + dead + lost to follow-up + transferred out). 
m). Cohort: A group of patients in whom TB has been diagnosed, and who were registered for 
treatment during a specified period (e.g., the cohort of new cases registered in the calendar year 
2014).  
 
3.2. Study Design  
A retrospective hospital-based cohort study of treatment outcomes of all TB patients registered 
from 1st January 2014 to 31st December 2019 in UPTH, Nigeria was conducted. Patients of all age 
groups (in years) who had started and completed a course of anti-TB treatment, or incomplete 
medical records (treatment outcome unknown), or transferred out during the study period were 
included in the study. Patients with MDR/XDR-TB, and patients transferred in to UPTH from 





3.3. Study Setting  
The study was conducted in UPTH, Port Harcourt, Rivers State, Niger Delta region, Southern 
Nigeria. The hospital is located behind the University of Port Harcourt, East-west Road, Choba, 
Obio/Akpor Local Government Area of Rivers State. Port Harcourt is an urban metropolis, mostly 
dominated by Christians (Ihejirika, 2009), with an estimated population of 3,020,000 in 2020 
(5.12% increase from 2019) (Macrotrends LLC, 2020; Population Stat, 2020). It is comprised 
mostly of a heterogenous group of people of different tribes and ethnicity, majority are the coastal 
people including Ikwerres, Ijaws, Ogonis, and among others (IRB, 2010). Many people who live 
in Port Harcourt are educated and have learned English at school (IRB, 2010). People living in 
rural areas sometimes visits UPTH for healthcare services. The tertiary care hospital is a federal 
government special referral hospital consisting of a TB treatment facility that is set up in 
accordance with the NTBLCP of Nigeria (Iwunze et al, 2017). The study area is an oil rich city 
with multinational oil companies whose business activities result in gas flaring and other sundry 






3.4. Variables: Outcomes and Determinants  
The outcome variable was treatment outcome, and could only one of the following: cured, 
treatment completed, treatment failure, died, loss to follow-up (defaulter), transferred out, or not 
evaluated. The determinant factors that we had included age (years), sex, HIV coinfection (+/-
/indeterminate), HIV patients receiving care/support (ART/CPT), diagnostic methods used for TB 
investigation (microscopy/Xpert/culture), type of TB (PTB/EPTB), type of patient 
(new/retreatment), and smear/culture/xpert MTB/RIF results (AFB/MTB/resistant). 
Figure 5: Map of Port Harcourt, Rivers State of Nigeria showing the study area. 




Socioeconomic status, education, employment, non-HIV comorbidities, and location were not 
available in the registers. 
 3.5. Data Collection 
 Data of all new and retreatment TB patients registered from January 1, 2014 to December 31, 
2019 were extracted from UPTH’s national TB programme (NTP) treatment registers. Relevant 
information about age, sex, HIV status, TB type, form of TB, diagnostic method used, HIV patients 
on ART/CPT, treatment regimen used, and treatment outcomes were collected and entered into 
EpiData software (version 4.6.02). Sample size for the study was considered and determined using 
OpenEpiTM (version 3.01) as described by Dean et al (2013). 
3.6. Data Management and Validation  
The records were entered into the EpiData software by two researchers. Error entries were 
corrected where possible to ensure the consistency and accuracy of data. There was plan to use 
culture data from the UPTH’s TB laboratory registers to validate the data extracted from NTP 
treatment registers. The researcher was assisted by one research assistant who was trained on data 
extraction from the TB registers and data entry into the software.  
3.7. Data Analysis  
Data processing and analyses were done using the statistical software package, IBM SPSS (version 
25.0, Armonk, NY, USA). Microsoft Excel (version 2103) was used to categorize data and plot 
graphs. Descriptive statistics was utilized to summarize patients’ characteristics across the 
outcome variables. Data comparisons were done using the Chi-square test or Fisher’s exact test if 
20% of expected cell values were ≤5 (Kapata et al, 2017; Holden et al, 2019). Associations 
between TB treatment outcomes and independent variables were assessed using the bivariate and 
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multivariate logistic regression models. The outcomes were categorized as successful (cured and 
treatment completed) and unsuccessful (lost to follow-up, failed, died, and transferred out) 
treatment outcomes. The data for patient’s age were categorized following standard WHO age 
groups for TB reports, and was as follows: 0 – 14, 15 – 24, 25 – 34, 35 – 44, 45 – 54, and ≥55 
years. A p-value of less than 0.05 (5%) was considered statistically significant at 95% confidence 
interval.  
3.8. Ethical Considerations  
Ethical approval (with reference number 154120) for this study was approved by Regional 
Committee for Medical and Health Research Ethics (REK), Norway. We also obtained approval 
for data collection from the UPTH’s Research Ethics Committee, Nigeria. Patients’ consent before 


















The findings of retrospective cohort study conducted at the UPTH, Port Harcourt, Nigeria 
presented a total of 816 participants. In the study, year 2015 had the highest number of TB patients 
195(23.9%), and year 2018 had the least TB cases 113(13.8%). Records of all TB patients 
registered in the hospitals’ DOTS center from January 1, 2014 to December 31, 2019 were 
reviewed and treatment outcomes were assessed, and factors that affected treatment outcomes were 
also identified. Result showed that 752(92.2%) and 63(7.7%) of the patients were placed on the 
standard anti-TB drugs (2HRZE/4HR), and on 2SHRZE/1HRZE/3HRE respectively. 
4.1 Basic Demographics and Clinical Characteristics of Participants 
The basic demographic and clinical characteristics of the patients are shown in Table 2. 
 
Table 2: Demographic and clinical characteristics of participants in UPTH, Nigeria (n=816) 
Variable 2014 2015 2016 2017 2018 2019 
All 
patients 
 n(%) n(%) n(%) n(%) n(%) n(%) n(%) 
Age (years) 
0 - 14   45(35.2) 58(29.7) 28(24.3) 19(15.3) 21(18.6) 24(17.0) 195(23.9) 
15 - 24  12(9.4) 24(12.3) 17(14.8) 13(10.5) 19(16.8) 30(21.3) 115(14.1) 
25 - 34 21(16.4) 38(19.5) 21(18.3) 30(24.2) 15(13.3) 26(18.4) 151(18.5) 
35 - 44 20(15.6) 32(16.4) 31(27.0) 24(19.4) 35(31.0) 30(21.3) 172(21.1) 
45 - 54 14(11.0) 26(13.3) 8(7.0) 23(18.5) 15(13.3) 21(14.9) 107(13.1) 
≥55 16(12.5) 17(8.7) 10(8.7) 15(12.1) 8(7.1) 10(7.1) 76(9.3) 
Total 128(100) 195(100) 115(100) 124(100) 113(100) 141(100) 816(100) 
Sex 
Male 65(50.8) 104(53.3) 59(51.3) 70(56.5) 68(60.2) 77(54.6) 443(54.3) 
Female 63(49.2) 91(46.7) 56(48.7) 54(43.5) 45(39.8) 64(45.4) 373(45.7) 
Total 128(100) 195(100) 115(100) 124(100) 113(100) 141(100) 816(100) 
Type of TB 
PTB 108(84.4) 148(75.9) 105(91.3) 99(79.8) 90(63.8) 128(90.8) 678(83.1) 
EPTB 18 (14.1) 25(12.8) 10(8.7) 25(20.2) 22(19.5) 13(9.2) 113(13.8) 
Missing 2(1.6) 22(11.3) 0(0.0) 0 1(0.9) 0(0.0) 25(3.1) 
Total 128(100) 195(100) 115(100) 124(100) 113(100) 141(100) 816(100) 
Type of patient 
New 112(87.5) 180(92.3) 99(86.1) 110(88.7) 104(92.0) 131(92.9) 736(90.2) 
Retreatment relapse 3(2.3) 4(2.1) 4(3.5) 8(6.5) 6(5.3) 3(2.1) 28(3.4) 
Retreatment after failure 3(2.3) 2(1.0) 4(3.5) 0(0.0) 1(0.9) 1(0.7) 11(1.3) 
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Retreatment after loss to 
follow-up 2(1.6) 3(1.5) 4(3.5) 4(3.2) 1(0.9) 3(2.1) 17(2.1) 
Retreatment, others 6(4.7) 4(2.1) 3(2.6) 0(0.0) 1(0.9) 2(1.4) 16(2.0) 
Missing 2(1.6) 2(1.0) 1(0.9) 2(1.6) 0(0.0) 1(0.7) 8(1.0) 
Total 128(100) 195(100) 115(100) 124(100) 113(100) 141(100) 816(100) 
HIV status 
Positive 59(46.1) 71(36.4) 50(43.5) 43(34.7) 39(34.5) 43(30.5) 305(37.4) 
Negative 65(50.8) 116(59.5) 65(56.5) 80(64.5) 73(64.6) 97(68.8) 496(60.8) 
Unknown 4(3.1) 8(4.1) 0(0.0) 1(0.8) 1(0.9) 1(0.7) 15(1.8) 
Total 128(100) 195(100) 115(100) 124(100) 113(100) 141(100) 816(100) 
HIV care & support 
On ART 57(44.5) 72(36.9) 50(43.5) 39(31.5) 37(32.7) 36(25.5) 291(35.7) 
Not on ART 71(55.5) 123(63.1) 65(56.5) 85(68.5) 76(67.3) 105(74.5) 525(64.3) 
                                                        
Total 128 195 115(100) 124(100) 113(100) 141(100) 816(100) 
On CPT 53(41.4) 71(36.4) 50(43.5) 39(31.5) 37(32.7) 36(25.5) 286(35.0) 
Not on CPT 75(58.6) 124(63.6) 65(56.5) 85(68.5) 76(67.3) 105(74.5) 530(65.0) 
                                                        
Total 128(100) 195(100) 115(100) 124(100) 113(100) 141(100) 816(100) 
Regimen 
Standard (2HRZE/4HR) 98(76.6) 186(95.4) 115(100.0) 115(92.7) 103(91.2) 135(95.7) 752(92.2) 
 
Retreatment (2SHRZE/ 
1HRZE/3HRE) 30(23.4) 9(4.6) 0(0.0) 9(7.3) 10(8.8) 5(3.5) 63(7.7) 
Missing 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 1(0.7) 1(0.1) 
                                                       
Total 128(100) 195(100) 115(100) 124(100) 113(100) 141(100) 816(100) 
Weight (Kg) 
0-14 35(27.8) 44(22.6) 18(15.7) 10(8.1) 13(11.5) 14(10.5) 134(16.6) 
15-24 11(8.7) 6(3.1) 7(6.1) 7(5.7) 6(5.3) 3(2.2) 40(5.0) 
25-34 2(1.6) 10(5.1) 5(4.4) 3(2.4) 3(2.7) 6(4.5) 29(3.6) 
35-44 8(6.4) 23(11.8) 9(7.8) 22(17.7) 14(12.4) 24(17.9) 100(12.4) 
45-54 31(24.6) 39(20.0) 35(30.4) 32(25.8) 35(31.0) 44(32.8) 216(26.8) 
55-64 24(19.1) 48(24.6) 32(27.8) 33(26.6) 24(21.2) 30(22.4) 191(23.7) 
65-74 12(9.5) 18(9.2) 6(5.2) 13(10.5) 15(13.3) 9(6.7) 73(9.1) 
≥75 3(2.4) 7(3.6) 3(2.6) 4(3.2) 3(2.7) 4(3.0) 24(3.0) 
                                                        






4.1.1. Age: The ages of participants were categorized into six segments: 0-14, 15-24, 25-34, 35-
44, 45-54, and ≥55 years as shown in Table 2. The mean age (± standard deviation, range) of the 
816 patients was approximately 30(±18.8, 1 – 86) years, with median age of 31 years. Majority of 
participants 195(23.9%) were in the age group of 0 – 14 years, out of which 91(29.8%) were HIV 
positive. While the least participant 76(9.3%) were in ≥55 years age category, out of which 
20(6.6%) were HIV positive. According to age groups (0-14 years, 15-24 years, 25-34 years, 35-
44 years, 45-54 years, and ≥55 years), a total of 736(90.2%) patients who were new on treatment 
were 186(25.3%), 101(13.7%), 136(18.5%), 155(21.1%), 94(12.8%), and 64(8.7%) respectively. 
In this study, TB patients whose age were less than 1 years old were recorded as 1 years old. The 




Figure 6: Age distribution of TB patients registered at UPTH, Port Harcourt, Nigeria (2014 – 





4.1.2. Weight: The pretreatment weight of the TB patients ranged from 2 to 97kg with mean(± 
standard deviation) weight of 43.9(±20.5)kg and median weight of 49 years. The distribution of 
their weight is shown in Figure 7. Two hundred and sixteen (26.8%) patients of category 45 – 54kg 
weighed the most, and the least participant’s weight 24(3.0%) was at category ≥75kg. 
 
 
4.1.3. Sex: Of the 816 participants in the study, more than half, 443(54.3%) were males, and 
373(45.7%) were females. Records of year 2015 had the highest number of males 104(53.3%) and 
females 91(46.7%); while year 2016 and 2018 had the least for males 59(51.3%), and females 
45(39.8%), respectively.  
 
Figure 7: Weight distribution of TB patients registered at UPTH, Port Harcourt, Nigeria (2014 – 




4.1.4. HIV status: The total number of PLWHIV was 305(37.4%), of which 153(50.2%) were 
males, and 152(49.8%) were females. The yearly and age distribution of TB patients according to 
their HIV status is shown in Figure 8a and Figure 8b respectively. In 2019, result showed a 39.4% 
reduction in the HIV co-infection rate from 2015. The distribution of HIV negative patients 
496(60.8%) were according to the ratio of 1.4 to 1 (285 males: 211 females), whereas 1 to 1 (153 
males: 152 females) ratio was for the HIV positives. Participants who do not have HIV status were 
15(1.8%). Of the total HIV infected patients, 291(95.4%) and 286(93.8%) were on ART and CPT, 









































































































Figure 9: Number of registered TB patients receiving HIV treatment at UPTH, Port Harcourt, 
Nigeria (2014 – 2019).  
 
Figure 8: b). HIV status by age groups of TB patients registered at UPTH, Port Harcourt, Nigeria 




4.1.5. Type of TB: There were a total of 678(83.1%) PTB, and 113(13.8%) EPTB patients, and 
25(3.1%) were missed cases. The highest PTB cases were recorded in year 2015 with a total of 
148(75.9%) and least in 2018 with 90(63.8%) patients. But in 2019, the number was 128(90.8%), 
a 13.5% reduction from 2015. Whereas for EPTB, year 2015 and 2017 showed the highest case 
with 25(12.8%) and 25(20.2%) respectively, representing 48.0% reduction in 2019 which had 
13(9.2%) patients.   
 
4.1.6. Type of TB patients: Of the 816 patients enrolled in this study, 736(90.2%) were new cases, 
and 72(8.8%) were retreatment cases. Out of the retreatment cases assessed, 28(3.4%) were 
relapsed patients, 11(1.3%) failed patients, 17(2.1%) after lost to follow-up patients, and 16(2.0%) 
were others. New cases were highest in 2015 with 180(92.3%), and lowest in 2016 with 99(86.1%) 
patients. While retreatment cases were highest in year 2016 with 15(13.0%) patients, it was lowest 














4.2. Diagnostic Characteristics of Participants 
The basic diagnostic characteristics of patients enrolled in the study is shown in Table 3.  
Table 3: Diagnostic characteristics of participants in UPTH, Nigeria (n=816) 
Variable 2014 2015 2016 2017 2018 2019 
All 
patients 
 n(%) n(%) n(%) n(%) n(%) n(%) n(%) 
Diagnostic method 
Smear microscopy 74(57.8) 118(60.5) 64(55.7) 37(29.8) 8(7.1) 5(3.5) 306(37.5) 
Xpert MTB/RIF 0 3(1.5) 22(19.1) 43(34.7) 54(47.8) 85(60.3) 207(25.4) 
Others 51(39.8) 71(36.4) 25(21.7) 39(31.5) 48(42.5) 48(34.0) 282(34.6) 
Missing 3(2.3) 3(1.5) 4(3.5) 5(4.0) 3(2.7) 3(2.1) 21(2.6) 
                                                        Total 128(100) 195(100) 115(100) 124(100) 113(100) 141(100) 816(100) 
Smear Microscopy result 
Negative 42(32.8) 49(25.1) 37(32.2) 40(32.3) 52(46.0) 72(51.1) 292(35.8) 
Positive: 1+ 12(9.4) 27(13.9) 39(33.9) 21(16.9) 0(0.0) 2(1.4) 101(12.4) 
Positive: 2+ 11(8.6) 19(9.7) 3(2.6) 2(1.6) 1(0.9) 0(0.0) 36(4.4) 
Positive: 3+ 8(6.3) 12(6.2) 1(0.9) 0(0.0) 1(0.9) 0(0.0) 22(2.7) 
Scanty 1(0.8) 16(8.2) 6(5.2) 1(0.8) 0(0.0) 0(0.0) 24(2.9) 
Missing 54(42.2) 72(40.0) 29(25.2) 60(48.4) 59(52.2) 67(47.5) 341(41.8) 
                                                        Total 128(100) 195(100) 115(100) 124(100) 113(100) 141(100) 816(100) 
Xpert MTB/RIF result 
Negative 2(1.6) 9(4.6) 26(22.6) 23(18.5) 14(12.3) 20(14.2) 94(11.5) 
MTB 0(0.0) 13(6.7) 48(41.7) 66(53.2) 50(44.2) 89(63.1) 266(32.6) 
Resistant 0(0.0) 3(1.5) 1(0.9) 0(0.0) 0(0.0) 0(0.0) 4(0.5) 
Missing 126(98.4) 170(87.2) 40(34.8) 35(28.2) 49(43.4) 32(22.7) 452(55.4) 
                                                        Total 128(100) 195(100) 115(100) 124(100) 113(100) 141(100) 816(100) 
 
4.2.1. Diagnostic methods: Smear microscopy was used to check for acid fast bacilli (AFB) in 
306(37.5%) patients. While Xpert MTB/RIF was used to diagnose 207(25.4%) patients for M. 
tuberculosis (MTB), as well as rifampicin resistance genes. Where both smear microscopy and 
gene Xpert MTB/RIF methods were used for a patient, we only recorded the former except where 
result of the later is positive or resistant because smear microscopy is traditionally used as a point-
of-care measure of bacillary burden in TB patients especially in a low resource setting like Nigeria. 
Two hundred and eighty-two (34.6%) other methods include clinical diagnosis, score charts, chest 
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X-Ray, magnetic resonance imaging (MRI), Mantoux test, and tissue pathology. Findings about 
the culture diagnostic method were not available for review because the National TB register do 
not contain information about culture. Data concerning the isolation of the TB pathogen by culture 
only exists at national and regional reference laboratories and not in DOTS centers (Oyefabi et al, 
2017). We made several efforts to retrieve data from NTBLCP regional reference laboratory at 
UPTH but not successful. 
4.2.2. Result of Smear Microscopy and Gene Xpert MTB/RIF: A total of 292(35.8%) smear 
microscopy showed a negative result, while 183(22.4%) smears including scanty smears produced 
a positive result for AFB (Table 3). Patients 22(2.7%), 36(4.4%), 101(12.4%), and 24(2.9%) had 
sputum grades 3+, 2+, 1+, and scanty, respectively. Of the smear positives, 172(94.0%) were PTB 
patients, whereas smear negative PTB were 257(88.0%), and 249(73.0%) smears were unknown.   
Out of 678 PTB patients that participated in this study, 158(23.3%) had new smear positive results 
at baseline, 226(33.3%) had new smear negative results, and 224(33.0%) new smear PTB patients 
had unknown sputum result (Table 4). Fourteen (2.1%) retreatment PTB patients had positive 
results, 29(4.3%) had retreatment smear negative results, and 21(3.1%) of the retreatment PTB 
patients had unknown sputum result at baseline (Table 5).  
In contrast, Gene Xpert MTB/RIF showed a negative result in 94(11.5%) patients enrolled in this 
study. It detected MTB in 266(32.6%) patients, and drug resistance in 4(0.5%) patients (Table 3). 
Between 2014 and 2019, the results produced through the gene Xpert technique showed a 
significant increase in the number of patients detected MTB.  
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Similarly, of the 678 PTB patients, gene Xpert technique detected MTB in 240(35.4%) new PTB 
patients at baseline. Sixty (8.8%) of the new PTB patients showed MTB negative results, 2(0.29%) 
had rifampicin resistant, and 305(45.0%) had unknown gene Xpert result.  
 
4.3. Treatment outcomes 
The study found that 226(27.7%) of 816 TB patients (new and retreatment) were cured, 208 
(25.5%) completed treatment, 15(1.8%) failed treatment, 110(13.5%) died, 109(13.4%) lost to 
follow-up, 90(11.0%) transferred out, and 58(7.1%) were not evaluated (Table 6; Figure 10). 
However, outcomes are usually analyzed separately for new and retreatment cases. Of the total 
158 new smear positive PTB patients at baseline, 76(48.1%) were confirmed cured based on 
bacteriological evidence, while 27(17.1%) patients completed treatment but had no bacteriological 
evidence to confirm cure. Five (3.2%) of the 158 patients failed treatment, 13(8.2%) died, 
18(11.4%) were lost to follow-up, 17(10.8%) were transferred out, and 2(1.3%) were not evaluated 
(Table 4). Treatment outcomes of new smear positive and negative PTB patients for each year 
from 2014 to 2019 were shown in Appendix 1 and 2.  
Of the total 240 new MTB positive PTB patients detected through gene Xpert, 121(50.4%) were 
cured, 20(8.3%) completed treatment, 8(3.3%) failed treatment, 26(10.8%) died, 22(9.2%) lost to 
follow-up, 22(9.2%) transferred out, and 21(8.8%) not evaluated (Table 4). The treatment 
outcomes for new and retreatment EPTB patients were found in Table 7. 
The distribution of treatment outcomes across all categories or strata of age, weight, sex, type of 
TB, type of patients, HIV status, etc. were shown in Appendix 3. The overall treatment ‘success’ 
(TSR) was 57.3%, and the ‘not success’ (UTO) was 42.7%. Between 2014 and 2015, there was no 
significant increase in TSR. Whereas between 2015 and 2016, a gradual but steady increase in 
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TSR occurred. But it declined in 2017 and increased again in 2018. The year, 2019 showed a slight 
decrease in TSR from 2018 (Figure 11). Comparisons of sex, type of patients, type of TB, and HIV 
status based on their treatment success and no success outcomes were each conducted at 5% level 
of statistical significance using the Chi-Square (Figure 12, Appendix 4). There was significant 
difference between male and female patients with reference to TSR and UTO (X2 = 7.08, p = 0.01). 
Females had better TSR (62.5%) more than the males (52.9%). For the type of patients, although 
new and retreatment cases had different TSR of 56.3% and 67.2% respectively, there was no 
significant difference between them (X2 = 2.95, p = 0.09). Whereas for the type of TB, there was 
significant difference between PTB and EPTB (X2 = 5.51, p = 0.02). The PTB patients had higher 
TSR (59.4%) when compared with EPTB patients (47.1%). The TSR of HIV negative patients was 
65.3%. It was higher than the TSR for HIV positive patients (46.1%). There was significant 
difference between patients infected with HIV and those not infected (X2 = 26.5, p = 0.00).  
Table 8 shows the crosstabulation of predictor variables associated with treatment outcomes of 












Table 5:  Treatment outcome stratified by microscopy and gene Xpert MTB/RIF result of the 
retreatment PTB patients registered at UPTH, Port Harcourt, Nigeria (2014 – 2019) 
Treatment outcomes Microscopy Gene Xpert 
 AFB + AFB - Unknown MTB + MTB - Resistant Unknown 
Cured 8 16 3 0 1 0 0 
Completed 2 6 5 0 1 0 2 
Failed 0 0 0 0 0 0 0 
Died 2 2 5 0 0 0 2 
Lost 1 4 4 0 0 0 0 
Transferred 1 1 1 0 0 0 0 
Not evaluated 0 0 3 0 0 0 0 
Total  14 29 21 0 2 0 4 
Percentage 2.1 4.3 3.1 0.0 0.3 0.0 0.6 
AFB+ = Acid fast bacilli positive; AFB- = Acid fast bacilli negative; MTB+ = Mycobacterium tuberculosis positive; 
MTB- = Mycobacterium tuberculosis negative 
 
Table 6:  Treatment outcomes of all registered TB patients, by year enrolled in UPTH, Port Harcourt, 
Nigeria (2014 – 2019; n = 816) 
Treatment 
outcomes   Years    Total  Percentage 
 2014 2015 2016 2017 2018 2019   
Cured 19 45 42 47 33 40 226 27.7 
Completed 45 50 35 19 34 25 208 25.5 
Failed 2 4 1 2 0 6 15 1.8 
Died 12 31 17 19 16 15 110 13.5 
Lost 34 23 12 13 10 17 109 13.4 
Transferred 15 35 5 17 13 5 90 11 
Not evaluated 1 7 3 7 7 33 58 7.1 
Total  128 195 115 124 113 141 816 100 
Percentage 15.7 23.9 14.1 15.2 13.8 17.3 100  
Table 4:  Treatment outcome stratified by microscopy and gene Xpert MTB/RIF result of the 
new PTB patients registered at UPTH, Port Harcourt, Nigeria (2014 – 2019)  
Treatment outcomes Microscopy Gene Xpert 
 AFB + AFB - Unknown MTB + MTB - Resistant Unknown 
Cured 76 107 9 121 18 0 53 
Completed 27 50 62 20 19 0 100 
Failed 5 4 2 8 0 0 3 
Died 13 18 48 26 5 1 47 
Lost 18 17 48 22 4 0 56 
Transferred 17 15 28 22 4 1 33 
Not evaluated 2 15 27 21 10 0 13 
Total  158 226 224 240 60 2 305 
Percentage 23.3 33.3 33.0 35.4 8.8 0.3 45.0 
AFB+ = Acid fast bacilli positive; AFB- = Acid fast bacilli negative; MTB+ = Mycobacterium tuberculosis positive; 






Table 7:  Treatment outcome stratified by microscopy and gene Xpert MTB/RIF results of new and retreatment 







































Cured 0 4 0 0 1 0 1 0 0 0 0 4 
Completed 2 10 0 2 26 2 10 0 0 1 0 29 
Failed 0 1 0 0 2 1 2 0 0 0 0 0 
Died 0 2 0 1 12 1 2 0 0 0 0 12 
Lost 1 4 0 0 10 2 0 0 0 0 0 13 
Transferred 1 4 0 0 16 2 2 0 0 0 0 17 
Not evaluated 0 3 0 0 5 0 2 0 0 1 1 6 
Total  4 28 0 3 72 8 19 0 0 2 1 31 
Percentage             
AFB+ = Acid fast bacilli positive; AFB- = Acid fast bacilli negative; MTB+ = Mycobacterium tuberculosis positive; MTB- = 
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Figure 10: Graphical representation of treatment outcomes of all registered TB patients 










































Figure 11: Trends of treatment success rates and unsuccessful treatment outcomes of all 
registered TB patients enrolled in UPTH, Port Harcourt, Nigeria (2014 – 2019). 
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Figure 12: Trends of treatment success rate and unsuccessful outcomes of registered TB patients in UPTH, 






Table 8: Crosstabulation of variables associated with treatment outcomes of registered TB 
patients in UPTH, Nigeria (n =816) 
Predictor 
variable 





Age (years)      
 0 - 14 93(50.5) 91(49.5)   
 15 – 24 78(72.9) 29(27.1)   
 25 – 34 95(68.8) 43(31.2) 29.5 0.00* 
 35 – 44 89(55.3) 72(44.7)   
 45 – 54 48(49.0) 50(51.0)   
 ≥55 31(44.3) 39(55.7)   
      
Sex      
 Male 219(52.9) 195(47.1)   
 Female 215(62.5) 129(37.5) 7.08 0.01* 
      
Type of TB      
 PTB 375(59.4) 256(40.6)   
 EPTB 48(47.1) 54(52.9) 5.51 0.02* 
      
Type of patients      
 New 385(56.3) 299(43.7)   
 Retreatment 45(67.2) 22(32.8) 2.95 0.09 
      
HIV status      
      Positive 129(46.1) 151(53.9)   
 Negative 303(65.3) 161(34.7) 26.5 0.00* 
      
ART      
 ART given 129(47.8) 141(52.2)   
 ART not 
given 
305(62.5) 183(37.5) 14.5 0.00* 
      
CPT      
 CPT given 127(47.9) 141(52.2)   
 CPT not given 307(62.3) 183(37.5) 15.4 0.00* 
      
Weight (kg)      
 15 – 97 377(60.2) 249(39.8)   
 0 – 14 55(43.7) 71(56.3) 11.8 0.001* 
Regimen      
 HRZE 406(58.1) 293(41.9)   
 SHRZE 28(47.5) 31(52.5) 2.51 0.1 
      
Diagnostic method      
 Microscopy 205(68.1) 96(31.9)   
 Xpert 
MTB/RIF 
108(59.3) 74(40.7) 3.82 0.05* 
Bacteriology      
      Smear result        AFB + 70(70.0) 30(30.0)   
              AFB - 20(55.6) 16(44.4) 2.49 0.1 
      Xpert result        MTB + 157(64.3) 87(35.7)   
        MTB - 59(72.8) 22(27.2) 1.97 0.2 
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4.4 Regression Analysis 
Table 9 shows results of bivariate regression analysis of treatment success by age groups adjusted 
for sex, type of patients, type of TB, HIV status, HIV treatment with ART and CPT, pretreatment 
weight, treatment regimen, diagnostic methods, and diagnostic results. The chance of treatment 
success among TB patients aged 0 – 14 years old (OR = 0.4, p = 0.00, 95%CI = 0.2 – 0.6, SE = 
0.26) was 0.4 times lower than in patients within the age category of 15 – 24 years. The TB patients 
aged ≥55 years (OR = 0.3, p = 0.00, 95%CI = 0.2 – 0.6, SE = 0.32) had 30% decreased risk of 
success when compared to the odds ratio of the outcome for patients aged 15 – 24 years old.  
Result revealed that female TB patients significantly achieved better treatment outcome (AOR = 
1.4, p = 0.03, 95% CI = 1.0 – 1.9, SE = 0.15) when compared with their male counterpart. The 
odds ratio of success was found to be not significantly higher in retreatment TB patients (AOR = 
1.6, p = 0.08, 95% CI = 1.0 – 2.8, SE = 0.28) compared with new TB patients. However, this 
represents 60% increased risk of success for retreatment cases when compared with new cases. 
The risk of treatment success was found to be higher in PTB patients (AOR = 0.6, p = 0.02, 95% 
CI = 0.4 – 0.9, SE = 0.22) than patients with EPTB. 
The risk of experiencing successful treatment outcome was 100% higher (double increase) for 
patients who were HIV negative (AOR = 2.0, p = 0.00, 95% CI = 1.5 – 2.8, SE = 0.16) than TB 
patients who were positive for HIV. The HIV coinfected TB patients who did not receive ART 
(AOR = 5.3, p = 0.2, 95% CI = 0.44 – 63.3, SE = 1.27), and CPT (AOR = 1.8, p = 0.5, 95% CI = 
0.4 – 9.3, SE = 0.84) were not significantly associated with the odds ratio of having treatment 
success when compared to HIV-TB patients on ART and CPT.  Patients weighted  2kg to 14kg 
were 40% less likely to have treatment success (AOR = 0.4, p = 0.01, 95% CI = 0.2 – 0.8, SE = 
0.32) than patients whose weight were between 15kg and 97kg.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
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The analysis also revealed that patients with smear negative AFB (AOR = 1.4, p = 0.2, 95%CI = 
0.9 – 2.1, SE = 0.21), and MTB negative results at baseline (AOR = 1.7, p = 0.08, 95%CI = 0.9 – 




















Table 9: Regression analysis of treatment success of registered TB patients in UPTH (n =816)  
Predictor variable  N(%) OR AOR p-value 95% CI SE 
Age (years)        
 0 - 14 195(23.9) 0.4 - 0.00* 0.2 – 0.6 0.26 
 15 – 24 115(14.1) reference -    
 25 – 34 151(18.5) 0.8 - 0.5 0.5 – 1.4  0.29 
 35 – 44 172(21.1) 0.5 - 0.004* 0.3 – 0.8 0.27 
 45 – 54 107(13.1) 0.4 - 0.001* 0.2 – 0.6 0.30 
 ≥55 76(9.3) 0.3 - 0.00* 0.2 – 0.6 0.32 
        
Sex        
 Male 443(54.3) reference reference    
 Female 373(45.7) 1.5 1.4 0.03* 1.0 – 1.9 0.15 
        
Type of TB        
 PTB 678(83.1) reference reference    
 EPTB 113(13.8) 0.6 0.6 0.02* 0.4 – 0.9 0.22 
        
Type of patients        
 New 736(90.2) reference reference    
 Retreatment 72(8.8) 1.6 1.6 0.08 0.9 – 2.8  0.28 
        
HIV status        
 Positive 305(37.4) reference reference    
 Negative 496(60.8) 2.2 2.0 0.00* 1.5 – 2.8 0.16 
        
ART        
 ART given 291(35.7) reference reference    
 ART not given 525(64.3) 0.2 5.3 0.2 0.4 – 63.3 1.27 
        
CPT        
 CPT given 286(35.0) reference reference    
 CPT not given 530(65.0) 0.6 1.8 0.5 0.4 – 9.3 0.84 
        
Weight (kg)        
 15 – 97 673(83.4) reference reference    
 0 – 14 134(16.6) 0.5 0.4 0.01* 0.2 – 0.8 0.32 
Regimen        
 HRZE 752(92.2) reference reference    
 SHRZE 63(7.7) 0.7 0.6 0.1 0.4 – 1.1 0.28 
        
Diagnostic method        
 Microscopy 306(37.5) reference reference    
 Xpert MTB/RIF 207(25.4) 0.7 0.7 0.03* 0.4 – 0.9 0.20 
Bacteriology        
      Smear result        AFB + 183(22.4) reference reference    
              AFB - 292(35.8) 0.5 1.4 0.2 0.9 – 2.1 0.21 
      Xpert result        MTB + 266(32.6) reference reference    
        MTB - 94(11.5) 1.5 1.7 0.08 0.9 – 3.0 0.30 
OR = Odds Ratio, AOR = Adjusted Odds Ratio, SE = Standard Error, N = Total number of TB cases, Asterisks 




5.1 Validity of the Study 
In this study, double data entries by two independent researchers were carried out and validated 
for inconsistencies. There was plan to use culture data from the TB laboratory register, and the 
NTBLCP regional reference laboratory TB register to validate the data extracted from NTP 
treatment registers. We were not able to retrieve these data for this study validation. However, 
based on the data collected, this study has a good internal validity because we were able to analyze 
and identify most of the main variables that affect the treatment outcomes that we see. Although, 
we are not able to draw causal inference regarding the impact of some potential confounding 
factors which may have affected the validity of this study, the roles of these confounders have been 
elucidated in many studies (Adejumo et al, 2017; Seid et al, 2017; Ogbuabor and Onwujekwe, 
2019). These confounders may be patient-centered factors, for example, socio-economic status, 
educational background, nutritional status, poverty, housing, occupation, alcohol, and drug abuse, 
as well as co-infection of TB with other health conditions like diabetes mellitus and neoplastic 
diseases (ATS, 2000; Adejumo et al, 2017; Ahmad et al, 2019); and healthcare system-related 
factors which includes accessibility and availability of TB services. Inadequate funding of TB 
program, poor health infrastructure, lack of training, staff shortages, low staff motivation, 
inappropriate prescription of drugs, irregular supplies of drugs, poor quality of drugs, poor policy 
implementation, and lack of political commitment (Nwokeukwu et al, 2013; Chukwu et al, 2016; 
Telisinghe et al, 2016; Aliyu et al, 2017; Oyefabi et al, 2017; Adejumo et al 2020) may directly or 
indirectly affect patients’ treatment outcomes. In Nigeria, there has been report of unreliable 
provision of isoniazid drugs due to logistic inefficiencies (Odume et al, 2020). This may have 
serious effect on treatment outcomes because uninterrupted provision of the drug is an essential 
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requirement for effective TB treatment. How well the outcome of this study is expected to apply 
to other settings is questionable since the study was a hospital-based study. 
 
5.2. Limitation of the Study 
In a retrospective study, researchers cannot control exposure or outcome assessment, and must rely 
on available documents or on others for an accurate record keeping. There is possibility of errors, 
underreported and missed data in the registers. In this study, reasons for loss to follow-up, and 
mortality rates were not included in the registers. The study analysis could not adjust for competing 
risk factors such as patient’s lifestyle, socioeconomic status, educational level, comorbidities 
(except HIV), and other potential confounders because data about them were not available. Also, 
information regarding side effects of anti-TB drugs were not available. Study was not able to 
estimate the impact of DR-TB on treatment outcomes because it was beyond its scope.  
5.3. Discussion of Main Findings 
5.3.1 Age: Out of the 736(90.2%) new TB patients registered for treatment in the hospital, majority 
186(25.3%) were in the age group of 0 – 14 years and were least 64(8.7%) in the age group of ≥55 
years. This is in conformity with a study in Pakistan, where majority of participants 178(36.1%) 
where ≤14 years old (Ahmad et al, 2019). Contrary to our findings, studies in Ethiopia (Tola et al, 
2019), and Nigeria (Sakajiki et al, 2018) have found majority of participants in the age group of 
25 – 34 years. Reason for high proportion of children may be due to referrals from many places 
because diagnosis of TB in children is a challenge (Trajman and Schwartzman, 2021); there has 
been a report of inadequate knowledge and skills in diagnosing and management of childhood TB 
particularly in Primary healthcare settings in Nigeria (FMoH, 2019); hence most private and non-
private facilities refer children to UPTH (a tertiary care hospital) for TB diagnosis. Further 
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inquiries about the reason why there is high proportion of children registered for TB treatment in 
the hospital revealed that in Nigeria once a patient is positive for either HIV or TB, all the 
occupants living with the infected person will have to be screened especially children because they 
are more at risk. In this study, majority of TB patients living with HIV were children 91(29.8%) 
aged 0-14 years old (Figure 8b). This suggests that children may have been infected with HIV 
through household contacts. The reason for lowest participation by older patients (≥55 years) may 
be because they are reasonably fragile, and heavily relied on family members for transport and 
assistance to health centers (Atif et al, 2018).  
There was a statistically significant association between age and treatment success (X2 = 29.5, p = 
0.00). This is consistent with some well-documented findings by Gebrezgabiher et al, 2016; 
Oyefabi et al, 2017; Ahmad et al, 2019; and Tola et al, 2019 where they respectively reported 
significant association between age and treatment success. 
5.3.2 Sex: Of the overall study participants, there was preponderance of males (54.3%) more than 
the female gender (45.7%). This agrees with national and global trends in which males are at more 
risk of TB infection (FMoH, 2019; WHO, 2019a). This may be due to a possible biological 
difference in susceptibility. Our finding is consistent with a previous evaluation at UPTH which 
revealed that between January 2015 and December 2018, approximately 54.0% male children were 
infected with TB more than the female children (Alex-Hart and Paul, 2019). Contrary to this, a 
study in Addis-Ababa Ethiopia have found a 55.4% female preponderance among children with 
TB (Tilahun and Gebre-Selassie, 2016).  In our study, reason for male preponderance may be 
attributed to underutilization of the DOTS services by females, more exposure to risk factors for 
TB than females, socio-cultural factors in the area that expose male to overcrowding which could 
lead them to becoming infected (Neyrolles and Quintana-murci, 2009; Gebrezgabiher et al, 2016; 
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Sakajiki et al, 2018), and could be as a result of drug abuse, smoking, and alcoholism (Musa et al, 
2011; Sunday et al, 2014). The logistic regression analysis showed that sex was significantly 
associated with treatment outcomes. This conforms with the reports from Ogbomosho, Nigeria 
(Oyefabi et al, 2017), Harar town, Ethiopia (Tola et al, 2019). 
5.3.3 Type of TB: The proportion of PTB patients was 678(83.1%) compared to EPTB 
113(13.8%), representing more than three-quarter of PTB patients enrolled in the programme. Of 
the PTB, 158(23.3%) had new smear positive result, and 226(33.3%) had new smear negative 
result. Well documented studies have found prevalence of PTB that were more than three-quarter 
(Sunday et al, 2014; Oyefabi et al, 2017; Alex-Hart and Paul, 2019). Children (≤14 years) were 
the majority in this study, hence there is possibility of overdiagnosis (WHO, 2019b). The low 
proportion of EPTB found may be due to the difficulties of diagnosing EPTB in the hospital. Type 
of TB was significantly associated with treatment outcomes. This evidence is supported by the 
study conducted in Southern Ethiopia by Gebrezgabiher et al (2016). It disagrees with other studies 
done by Sunday et al (2014), and Tola et al (2019) where they found treatment outcome not 
significantly associated with type of TB. 
 
5.3.4 HIV status: The referral facility account for a high proportion of HIV cases. The WHO has 
recommended compulsory TB treatment for PLWHIV. This study found that 305(37.4%) of TB 
patients had HIV infection. Previous studies have shown 42.7% (Ofoegbu and Odume, 2015), 
19.1% (Oyefabi et al, 2017), 48.5% (Alex-Hart and Paul, 2019), 18.8% (Abdulkader et al, 2019), 
and 22.8% (Tola et al, 2019) HIV coinfection prevalence rate in TB patients. In 2019, result 
showed a decreasing 39.4% of HIV positive TB patients from 2015. This may indicate that more 
HIV infected patients are still not receiving TB treatment. This is supported by the Federal Ministry 
of Health, Nigeria position that over 40,000 HIV positive TB cases are missed, based on the 
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estimated TB cases in the country (FMoH, 2019). Globally, the prevalence of HIV has been 
reported to be higher among females when compared with males (UNAIDS, 2021). But findings 
in this study show an almost equal prevalence in both male 153(50.2%) and females 152(49.8%). 
This corroborates the findings of Ofoegbu and Odume (2015) which found almost the same 
prevalence in both male (42.7%) and female (42.6%) TB patients at National Hospital Abuja, 
Nigeria. This pattern may reflect the increasingly risky behaviour in men.  The risk of experiencing 
treatment success was 100% higher (double increase) for patients who were HIV negative than the 
TB patients who were positive for HIV. This finding supports other similar studies indicating that 
HIV-TB coinfected patients have significantly lower TSR compared to TB patients who are not 
infected with HIV (Ofoegbu and Odume, 2015; Abdulkader et al, 2019). HIV-TB coinfected 
patients who neither receive ART nor CPT showed no significant improvement in treatment 
outcome when compared to HIV-TB patients on ART and CPT. The WHO recommended the use 
of both treatments singly or together in HIV positive - TB patients (WHO, 2012). These therapies 
(ART and CPT) are well-known to provide synergistic effects when both are taking together, and 
they reduce death rate, as well improve treatment success in HIV-TB coinfected patients (Blanc et 
al, 2011; Suthar et al, 2012; Sawadogo et al, 2015). 
5.3.5 Treatment outcomes: Findings from this assessment showed that out of the overall patients 
registered in the hospital for TB treatment, 226(27.7%) were cured, 208(25.5%) completed 
treatment, 15(1.8%) failed treatment, 110(13.5%) died, 109(13.4%) were lost to follow-up, 
90(11.0%) transferred out, and 58(7.1%) were not evaluated. Categorically, result of treatment 
outcomes in new smear positive PTB patients show that 76(48.1%) were cured, 27(17.1%) 
completed treatment, 5(3.2%) failed treatment, 13(8.2%) died, 18(11.4%) lost to follow-up, 
17(10.8%) transferred out, and 2(1.3%) were not evaluated.  Findings on new smear positive PTB 
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patients who were cured contrasts with studies in Zaria, Nigeria (Oyefabi et al, 2017); Harar (Tola 
et al, 2019), Addis-Ababa (Fentie et al, 2020) Ethiopia; and in Shangla, Pakistan (Ahmad et al, 
2019) which reported a lower proportion of patients bacteriologically confirmed cured. 
The high proportion of patients that completed treatment may indicate insufficient bacteriological 
evidence to confirm cure at the end of treatment. The high failure rate could be attributed to 
irregular drug supply, poor quality of drugs or poor treatment adherence (Oyefabi et al, 2017) or 
drug resistance. The high proportion of death may be related to the high prevalence of HIV 
infection among cases, this is because PLWHIV are more likely to die from TB disease than people 
uninfected with HIV (UNAID, 2017). The cause of death may also be attributed to the poor 
functioning of programme. Government’s political commitment towards fighting the scourge of 
TB in Nigeria is not enough (Vanguard, 2018). The high number of patients lost to follow-up may 
be due to lack of socioeconomic interventions (san Lin, 2019), thus suggesting a possible risk of 
drug resistance. More patients were lost to follow-up in 2014 than in any other years, this may be 
due to the political instability ahead of 2015 general election in Nigeria (ICG, 2014). The overall 
TSR in this study was 57.3%. However, this result is lower than the national target of 85%. It is 
also lower than the overall success rates of 83.1% (Sakajiki et al, 2018), 85.2% (Gebrezgabiher et 
al, 2016), and 94.93% (Ahmad et al, 2019) reported from Nigeria, Ethiopia, and Pakistan, 
respectively. The relatively lower success rate could be attributed to poor level of TB knowledge 
among patients (Adepoju, 2020), poor monitoring of adherence to treatment to ensure successful 
completion using DOT (Oyediran, 2019), and risk factors for the prevalence of TB among the 






The assessment of treatment outcomes of registered TB patients in UPTH, Nigeria between 2014 
and 2019 showed a 57.3% overall TSR. This was lower than the 85% national target for TB 
treatment. The study provides evidence that age, sex, HIV, type of TB, pretreatment weight, and 
diagnostic methods associated significantly with TB treatment outcome. There is need to cut TB 
transmission and eliminate the source of infection by treating cases; and detected cases should be 
adequately followed-up. Strengthening National TB control program, and partnership with local 
organizations and communities will help to accelerate the decline in TB mortality and morbidity 
to reach the ambitious sustainable development goals (SDGs) of ≥90% treatment success outcomes 
by 2030. There is also the need for National Agency for the Control of AIDS (NACA) program to 
scale-up its activities to ensure that all the people who tested positive for HIV are placed on anti-
TB therapy, ART, and CPT for improved health. Other factors affecting TB control in UPTH and 
in Nigeria at large should be identified, elucidated, and addressed. Hence, there should be further 
study, preferably a systematic review to pool the findings of several studies, on the factors affecting 
TB control, and on the challenges or experiences of TB patients, healthcare providers, and 












Abdulkader M, van Aken I, Niguse S, Hailekiros H, Spigt M. Treatment outcomes and their 
 trend among tuberculosis patients treated at peripheral health settings of Northern 
 Ethiopia between 2009 and 2014: a registry-based retrospective analysis. BMC Research 
 Notes. 2019 Dec;12(1):1-5. 
Adejumo OA, Daniel OJ, Otesanya AF, Salisu-Olatunj SO, Abdur-Razzaq HA. Evaluation of 
 outcomes of tuberculosis management in private for profit and private-not-for profit 
 directly observed treatment short course facilities in Lagos State, Nigeria. journal of the 
 Nigeria Medical Association. 2017 Jan;58(1):44. 
Adejumo OA, Daniel OJ, Adepoju VA, Femi-Adebayo T, Adebayo BI, Airauhi AO. Challenges 
 of tuberculosis control in Lagos state, Nigeria: A qualitative study of health-care providers' 
 perspectives. Nigerian medical journal: journal of the Nigeria Medical Association. 2020 
 Jan;61(1):37. 
Adepoju P. Nigeria's widening tuberculosis gap. The Lancet Infectious Diseases. 2020 Jan 
 1;20(1):29. 
Ahmad T, Khan M, Khan MM, Ejeta E, Karami M, Ohia C. Treatment outcome of tuberculosis 
 patients under directly observed treatment short course and its determinants in Shangla, 
 Khyber-Pakhtunkhwa, Pakistan: a retrospective study. International journal of 
 mycobacteriology. 2017 Oct 1;6(4):360. 
Aït-Khaled N, Alarcón E, Armengol R, Bissell K, Boillot F, Caminero JA, Chiang CY, 
 Clevenbergh P, Dlodlo R, Enarson DA, Enarson P, Fujiwara PI, Harries AD, Heldal E, 
 Hinderaker SG, Monedero I, Reider HL, Rusen ID, Trebucq A, Van Deun A, Wilson N. 
 Management of tuberculosis: A Guide to the Essentials of Good Practice. International 
 Union Against Tuberculosis and Lung Disease. Paris, France. 2010. 
Alex-Hart BA, Paul NI. Pattern and Outcome of Childhood Tuberculosis Seen at the University 
 of Port Harcourt Teaching Hospital, Nigeria. Journal of Tuberculosis Research. 2019 Sep 
 29;7(03):170. 
Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, Nahid P. Adherence 
 interventions and outcomes of tuberculosis treatment: A systematic review and meta-
 analysis of trials and observational studies. PLoS medicine. 2018 Jul 3;15(7):e1002595. 
Aliyu G, Ezati N, Iwakun M, Peters S, Abimiku AL. Diagnostic system strengthening for drug 
 resistant tuberculosis in Nigeria: impact and challenges. African journal of laboratory 
 medicine. 2017;6(2):1-6.  
American Lung Association (ALA) Tuberculosis. USA. 2020. https://www.lung.org/lung-health-
 diseases/lung-disease-lookup/tuberculosis [Accessed 26.10.2020] 
American Thoracic Society (ATS). Diagnostic standards and classification of tuberculosis in 
 adults and children. Am J Respir Crit Care Med. 2000;161:1376-95. 
56 
 
Atif M, Anwar Z, Fatima RK, Malik I, Asghar S, Scahill S. Analysis of tuberculosis treatment 
 outcomes among pulmonary tuberculosis patients in Bahawalpur, Pakistan. BMC research 
 notes. 2018 Dec 1;11(1):370. 
Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: from the first 
 historical records to the isolation of Koch's bacillus. Journal of preventive medicine and 
 hygiene. 2017 Mar;58(1):E9. 
Beatrice NS, Frank MD, Ugochukwu PA. Factors associated with non-compliance to treatment 
 regimen among tuberculosis patients in University of Port Harcourt Teaching Hospital, 
 Rivers State. Worldwide journal of multidisciplinary research and development. 
 2017;3(4):62-66. 
Bhalla AS, Goyal A, Guleria R, Gupta AK. Chest tuberculosis: Radiological review and imaging 
 recommendations. Indian J Radiol Imaging. 2015 Jul-Sep;25(3):213-25.  
Bieh KL, Weigel R, Smith H. Hospitalized care for MDR-TB in Port Harcourt, Nigeria: a 
 qualitative study. BMC infectious diseases. 2017 Dec;17(1):50. 
Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan 
 S, Prak N, Kim C. Earlier versus later start of antiretroviral therapy in HIV-infected adults 
 with tuberculosis. New England Journal of Medicine. 2011 Oct 20;365(16):1471-81. 
Bloom BR, Atun R, Cohen T. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, et al., 
 editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank 
 for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 
 11. Available from: https://www.ncbi.nlm.nih.gov/books/NBK525174/ doi: 10.1596/978-
 1-4648-0524-0_ch11 
Cambier CJ, Falkow S, Ramakrishnan L. Host evasion and exploitation schemes of 
 Mycobacterium tuberculosis. Cell. 2014 Dec 18;159(7):1497-509. 
Cayci YT, Bilgin K, Coban AY, Birinci A, Durupınar B. An evaluation of false-positive 
 rifampicin resistance on the Xpert MTB/RIF. Mem Inst Oswaldo Cruz. 2017 
 Nov;112(11):756-759.  
Central Intelligence Agency. Nigeria. 2019 https://www.cia.gov/library/publications/the-world-
 factbook/geos/print_ni.html [Accessed 24.02.2020] 
Centers for Disease Control and Prevention (CDC) Fact sheets: tuberculosis. 2014a Oct 20.  
 https://www.cdc.gov/tb/publications/factsheets/general/ltbiandactivetb.htm [Accessed 
 25.10.2020] 
CDC. Chapter 2: Transmission and Pathogenesis of Tuberculosis. Core Curriculum on 
 Tuberculosis: What the Clinician Should Know. 2014b. 
 https://www.cdc.gov/tb/education/corecurr/pdf/chapter2.pdf [Accessed 04.05.2021] 
CDC. Basic TB facts: Latent TB infection and TB diseases. 2016a
 https://www.cdc.gov/tb/topic/basics/tbinfectiondisease.htm  [Accessed 18.11.2020] 
57 
 
CDC. Basic TB facts: Signs and symptoms. 2016b. 
 https://www.cdc.gov/tb/topic/basics/signsandsymptoms.html [Accessed 18.11.2020] 
CDC. Lesson 6: treatment of TB disease. USA, 2016c. https://www.cdc.gov/tb/ 
 webcourses/tb101/page3832.html [Accessed 01.02.2020].  
CDC. Lesson 6: treatment of TB disease. 2016d. 
 https://www.cdc.gov/tb/webcourses/tb101/page3832.html  [Accessed 01.02.2020].  
Chakaya J, Kirenga B, Getahun H. Long term complications after completion of pulmonary 
 tuberculosis treatment: a quest for a public health approach. Journal of Clinical 
 Tuberculosis and other Mycobacterial Diseases. 2026;3:10-12 
Chisholm RH, Tanaka MM. The emergence of latent infection in the early evolution of 
 Mycobacterium tuberculosis. Proc Biol Sci. 2016 May 25;283(1831):20160499.  
Chukwu JN, Ukwaja KN, Ekeke N, Nwafor CC, Meka AO, Madichie NO, Anyim MC, 
 Ogbudebe C, Adegbesan J, Ikebudu J, Oshi DC. Assessment of current practices in 
 management of childhood TB among frontline clinicians in Southern Nigeria. 
 International health. 2016 Jul 1;8(4):269-76. 
Daniel TM. Hermann Brehmer and the origins of tuberculosis sanatoria [Founders of our 
 knowledge]. The International Journal of Tuberculosis and Lung Disease. 2011 Feb 
 1;15(2):161-2. 
Dean AG, Sullivan KM, Soe MM. Open source epidemiologic statistics for public health. 2013 
 https://www.openepi.com/SampleSize/SSPropor.htm [Accesses 22.06.2021]. 
Delgado BJ, Bajaj T. Ghon Complex. [Updated 2020 Sep 21]. In: StatPearls [Internet]. Treasure 
 Island (FL): StatPearls Publishing; 2020 Jan-. Available from: 
 https://www.ncbi.nlm.nih.gov/books/NBK551706/ 
de Martino M, Lodi L, Galli L, Chiappini E. Immune response to Mycobacterium tuberculosis: a 
 narrative review. Frontiers in pediatrics. 2019 Aug 27;7:350. 
den Hertog AL, Visser DW, Ingham CJ, Fey FH, Klatser PR, Anthony RM. Simplified 
 automated image analysis for detection and phenotyping of Mycobacterium tuberculosis 
 on porous supports by monitoring growing microcolonies. PLoS One. 2010 Jun 
 8;5(6):e11008.  
Donoghue HD, Spigelman M, Greenblatt CL, Lev-Maor G, Bar-Gal GK, Matheson C, Vernon 
 K, Nerlich AG, Zink AR. Tuberculosis: from prehistory to Robert Koch, as revealed by 
 ancient DNA. The Lancet infectious diseases. 2004 Sep 1;4(9):584-92. 
Dorman SE, Chihota VN, Lewis JJ, Shah M, Clark D, Grant AD, Churchyard GJ, Fielding KL. 
 Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis 
 prevalence survey. PloS one. 2012 Aug 15;7(8):e43307. 
58 
 
Dutta NK, Karakousis PC. Latent tuberculosis infection: myths, models, and molecular 
 mechanisms. Microbiol Mol Biol Rev. 2014 Sep;78(3):343-71.  
Ejeta E, Beyene G, Balay G, Bonsa Z, Abebe G. Factors associated with unsuccessful treatment 
 outcome in tuberculosis patients among refugees and their surrounding communities in 
 Gambella Regional State, Ethiopia. PloS one. 2018;13(10). 
European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in 
 support of TB diagnosis. Stockholm: ECDC; 2011. 
 https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/1103_G
 UI_IGRA.pdf . 
European Centre for Disease Prevention and Control. Handbook on tuberculosis laboratory 
 diagnostic methods in the European Union – Updated 2018. Stockholm: ECDC; Aug. 
 2018. https://www.ecdc.europa.eu/sites/default/files/documents/TB-handbook-2018-
 final.pdf. 
Federal Ministry of Health Nigeria. National TB and Leprosy Control Program: Workers manual. 
 5th ed. Abuja, Nigeria 2010. https://www.who.int/hiv/pub/guidelines/nigeria_tb.pdf. 
Federal Ministry of Health Nigeria. National TB and Leprosy Control Program: The national 
 strategic plan  for tuberculosis control, NSP-TB 2015 – 2020: Towards Universal Access 
 to Prevention,  Diagnosis and Treatment. Abuja, Nigeria, 2014. 
Federal Ministry of Health Nigeria. 2019 annual tuberculosis report. Abuja, Nigeria 2019. 
 https://www.health.gov.ng/doc/Draft-2019-NTBLCP-Annual-report-22032020.pdf 
Fentie AM, Jorgi T, Assefa T. Tuberculosis treatment outcome among patients treated in public 
 primary healthcare facility, Addis Ababa, Ethiopia: a retrospective study. Archives of 
 Public Health. 2020 Dec;78(1):1-9.  
Flores-Valdez MA. Uncovering the hidden: complexity and strategies for diagnosing latent 
 tuberculosis. Microb Cell. 2017 Oct 24;4(11):365-367.  
Gebrezgabiher G, Gebremedhin Romha EE, Asebe G, Zemene E, Ameni G. Treatment outcome 
 of tuberculosis patients under directly observed treatment short course and factors affecting 
 outcome in southern Ethiopia: a five-year retrospective study. PloS one. 2016 Feb 26;11(2). 
Geng E, Kreiswirth B, Burzynski J, Schluger NW. Clinical and radiographic correlates of 
 primary and reactivation tuberculosis: a molecular epidemiology study. Jama. 2005 Jun 
 8;293(22):2740-2745. 
Gideon HP, Flynn JL. Latent tuberculosis: what the host "sees"? Immunol Res. 2011 Aug;50(2-
 3):202-212.  
Gordon SV, Parish T. Microbe Profile: Mycobacterium tuberculosis: Humanity's deadly 
 microbial foe. Microbiology. 2018 Apr 1;164(4):437-439. 
59 
 
Heemskerk D, Caws M, Marais B, et al. Tuberculosis in Adults and Children. London: Springer; 
 2015. Chapter 2, Pathogenesis. Available from: 
 https://www.ncbi.nlm.nih.gov/books/NBK344406/. 
Holden IK, Lillebaek T, Seersholm N, Andersen PH, Wejse C, Johansen IS. Predictors for 
 pulmonary tuberculosis treatment outcome in Denmark 2009–2014. Scientific reports. 
 2019 Sep 10;9(1):1-8. 
Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical review. 
 Tuberculosis (Edinb). 2011 Nov 1;91(6):497-509.  
Ihejirika WC. Muslim minorities and media access in a predominantly Christian city: The case of 
 Port Harcourt, Nigeria. Journal of African Media Studies. 2009 Dec 1;1(3):469-91. 
Ikechukwu EE. Socio-Economic Impacts of Flooding on the Residents of Port Harcourt Metropolis 
 in Rivers State, Nigeria. Natural resources. 2015 Jan 14;6(01):1. 
Immigration and Refugee Board of Canada, Nigeria: Information on the demographic profile of 
 Port Harcourt, including the percentage of Igbo residents; whether Igbo who relocate to 
 Port Harcourt experience social, economic or linguistic difficulties, 2010 October 
 20, NGA103625.E, available at: https://www.refworld.org/docid/4e4a21682.html 
 [Accessed 06.04.2020] 
Institute for health metrics and evaluation (IHME) What causes the most premature death in 
 Nigeria? WA, USA, 2017 [Accessed 21.12.2019]. 
International Crisis Group (ICG), Nigeria’s dangerous 2015 elections: limiting the violence; Africa 
 Report No. 220, Belgium. 2014 Nov. 21. 
  https://reliefweb.int/sites/reliefweb.int/files/resources/220-nigeria-s-dangerous-2015-
 elections-limiting-the-violence.pdf 
Iwunze EC, Okeafor IN, IBEH C, Okeafor In. Pattern of intensive phase treatment outcomes 
 of multi-drug resistant tuberculosis in University of Port Harcourt treatment centre: 
 a review of records from inception till 2016. Orient Journal of Medicine. 2017 
 Jul;29(3-4):106-11. 
Izudi J, Semakula D, Sennono R, Tamwesigire IK, Bajunirwe F. Treatment success rate among 
 adult pulmonary tuberculosis patients in sub-Saharan Africa: a systematic review and meta-
 analysis. BMJ open. 2019 Sep 1;9(9):e029400. 
Jilani TN, Avula A, Zafar Gondal A, et al. Active Tuberculosis. [Updated 2020 Aug 10]. In: 
 StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available 
 from: https://www.ncbi.nlm.nih.gov/books/NBK513246/. 
60 
 
Jørstad MD, Aẞmus J, Marijani M, Sviland L, Mustafa T. Diagnostic delay in extrapulmonary 
 tuberculosis and impact on patient morbidity: A study from Zanzibar. PloS one.  2018 
 Sep 6;13(9). 
Joseph BN, Sariem CN, Dangiwa DA, David S, Joseph SI, Egoh DZ. Comparative assessment of 
 Directly Observed Treatment Short course (DOTS) for tuberculosis in a primary and a 
 tertiary health centre in Nigeria. J Pharm Bioresources. 2015;12(1):22-9. 
Kapata N, Grobusch MP, Chongwe G, Chanda-Kapata P, Ngosa W, Tembo M, Musonda S, 
 Katemangwe P, Bates M, Mwaba P, Zumla A. Outcomes of multidrug-resistant 
 tuberculosis in Zambia: a cohort analysis. Infection. 2017 Dec 1;45(6):831-9. 
Knight GM, Dyakova E, Mookerjee S, Davies F, Brannigan ET, Otter JA, Holmes AH. Fast and 
 expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to 
 explore screening for carbapenem resistance in UK hospitals. BMC medicine. 2018 Dec 
 1;16(1):141. 
Koch R. Die Äetiologie der Tuberkulose. Berliner klinische Wochenschrift 1882 
Koppaka R, Bock N. How reliable is chest radiography?. In: Frieden, T. 2nd ed. Toman’s 
 tuberculosis case detection, treatment, and monitoring: questions and answers, WHO, 
 2004 Jun 23; 51-60. 
Kroon EE, Kinnear CJ, Orlova M, Fischinger S, Shin S, Boolay S, Walzl G, Jacobs A, Wilkinson 
 RJ, Alter G, Schurr E. An observational study identifying highly tuberculosis-exposed, 
 HIV-1-positive but persistently TB, tuberculin and IGRA negative persons with M. 
 tuberculosis specific antibodies in Cape Town, South Africa. EBioMedicine. 2020 Nov 
 1;61:103053. 
Laghari M, Sulaiman SA, Khan AH, Memon N. A prospective study of socio-demographic, 
 clinical characteristics and treatment outcomes of children with tuberculosis in Sindh, 
 Pakistan. BMC infectious diseases. 2019 Dec 1;19(1):82. 
Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, 
 Zijenah L, Kapata N, Abubakar I, McNerney R, Hoelscher M, Memish ZA, Migliori GB, 
 Kim P, Maeurer M, Schito M, Zumla A. Advances in tuberculosis diagnostics: the Xpert 
 MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013 
 Apr;13(4):349-61.  
Lee HS, Park KU, Park JO, Chang HE, Song J, Choe G. Rapid, sensitive, and specific detection 
 of Mycobacterium tuberculosis complex by real-time PCR on paraffin-embedded human 
 tissues. J Mol Diagn. 2011 Jul;13(4):390-4. 
Leyten EM, Prins C, Bossink AW, Thijsen S, Ottenhoff TH, Van Dissel JT, Arend SM. Effect of 
 tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-γ assay. 
 European Respiratory Journal. 2007 Jun 1;29(6):1212-6. 
61 
 
MacPherson P, Lebina L, Motsomi K, Bosch Z, Milovanovic M, Ratsela A, Lala S, Variava E, 
 Golub JE, Webb EL, Martinson NA. Prevalence and risk factors for latent tuberculosis 
 infection among household contacts of index cases in two South African provinces: 
 Analysis of baseline data from a cluster-randomised trial. PLoS One. 2020 Mar 
 17;15(3):e0230376 
Macrotrends LLC. Port Harcourt, Nigeria population 1950 – 2020, 2020 <a 
 href='https://www.macrotrends.net/cities/22018/port-harcourt/population'>Port 
 Harcourt, Nigeria Population 1950-2020</a>. www.macrotrends.net. [Accessed 
 05.04.2020]. 
Neyrolles O, Quintana-Murci L. Sexual inequality in tuberculosis. PLoS medicine. 2009 
 Dec;6(12). 
Ngabonziza JC, Decroo T, Migambi P, Habimana YM, Van Deun A, Meehan CJ, Torrea G, 
 Massou F, de Rijk WB, Ushizimpumu B, Niyigena EB. Prevalence and drivers of false-
 positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in 
 Rwanda. The Lancet Microbe. 2020 Jun 1;1(2):e74-83. 
Migliori GB, D'Ambrosio L, Centis R. Tuberculosis: an ancient and evergreen disease. European 
 Respiratory Review 2011, 20: 69-70. 
Müller A. Information for activists, patients, heath workers & researchers working to end 
 tuberculosis. 2016 March 31.  http://www.tbonline.info/posts/2016/3/31/extrapulmonary-
 tb   
Murray JF, Schraufnagel DE, Hopewell PC. Treatment of tuberculosis. A historical perspective. 
 Annals of the American Thoracic Society. 2015 Dec;12(12):1749-59. 
Musa BM, Uloko AE, Gebi U, Etiebet M, Dakum P, Blattner W. Treatment outcome of 
 tuberculosis-HIV co-infection in North-Central Nigeria. Sahel Medical Journal. 2011 Jul 
 – Sep 3: 136-139 
Nwokeukwu HI, Okafor PN, Okorie O, Ukpabi IK. Paediatric multidrug-resistant tuberculosis 
 with HIV coinfection: a case report. Case reports in medicine. 2013 Jan 23;2013. 
Odume B, Meribe SC, Odusote T, Ifunanya M, Debem H, Amazue-Ezeuko I, Ogbanufe O, 
 Adamu Y, Onotu D. Taking tuberculosis preventive therapy implementation to national 
 scale: the Nigerian PEPFAR Program experience. Public Health Action. 2020 Mar 
 21;10(1):7-10. 
Ofoegbu OS, Odume BB. Treatment outcome of tuberculosis patients at National Hospital Abuja 
 Nigeria: a five-year retrospective study. South African Family Practice. 2015 Jan 
 2;57(1):50-6. 
Ogbuabor DC, Onwujekwe OE. Governance of tuberculosis control programme in Nigeria. 
 Infectious diseases of poverty. 2019 Dec;8(1):1-1. 
62 
 
Ogbudebe CL, Izuogu S, Abu CE. Magnitude and treatment outcomes of pulmonary tuberculosis 
 patients in a poor urban slum of Abia State, Nigeria. International journal of 
 mycobacteriology. 2016 Jun 1;5(2):205-10. 
Olaru ID, Heyckendorf J, Grossmann S, Lange C. Time to culture positivity and sputum smear 
 microscopy during tuberculosis therapy. PLoS One. 2014 Aug 29;9(8):e106075. 
Oyediran, K. (2019). Quality of Tuberculosis Services Assessment in Nigeria: Report. Chapel Hill, 
 NC, USA: MEASURE Evaluation, University of North Carolina. 
Oyefabi A, Adetiba E, Leeshak E, Adesigbin O. Tuberculosis and the determinants of treatment 
 outcome in Zaria, North Western Nigeria–A nine-year (2007–2015) epidemiological 
 review. Journal of Medicine in the Tropics. 2017 Jul 1;19(2):116. 
Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC. Nature reviews disease 
 primers. Tuberculosis. 2016;2:16076.  
Pfyffer GE, Auckenthaler R, van Embden JD, van Soolingen D. Mycobacterium canettii, the 
 smooth variant of M. tuberculosis, isolated from a Swiss patient exposed in Africa. 
 Emerg Infect Dis. 1998 Oct-Dec;4(4):631-4.  
Population stat. Port Harcourt, Nigeria population, world statistical data, 2020  
 https://populationstat.com/nigeria/port-harcourt [Accessed 06.04.2020] 
Public Health Ontario (PHO) Ontario Agency for Health Protection and Promotion (Public 
 Health Ontario). Focus On: Testing for Mycobacterium tuberculosis with interferon 
 gamma release assays. Toronto, ON: Queen’s Printer for Ontario; 2019. 
Ramirez-Lapausa M, Menendez-Saldana A, Noguerado-Asensio A. Extrapulmonary 
 tuberculosis: an overview. Rev Esp Sanid Penit. 2015;17(1):3-11. 
Reece TB, Zakowski P, Mitchell JD. 16-Thoracic surgical considerations in infectious and 
 inflammatory diseases of the lung. Medical management of the thoracic surgery patient. 
 2010:154-174. 
Reed JL, Walker ZJ, Basu D, Allen V, Nicol MP, Kelso DM, McFall SM. Highly sensitive 
 sequence specific qPCR detection of Mycobacterium tuberculosis complex in respiratory 
 specimens. Tuberculosis (Edinb). 2016 Dec;101:114-124. 
San Lin K. Loss to Follow-Up (LTFU) during Tuberculosis Treatment. InHealthcare Access-
 Regional Overviews 2019 Sep 16. IntechOpen.  
Sakajiki MA, Garba B, Ibrahim Y, Mohammed BA, Abdullahi U, Sada KB, Ibrahim TM. 
 Treatment outcome of Tuberculosis at a specialist hospital in North Western Nigeria-A 30 




Saktiawati AM, Putera DD, Setyawan A, Mahendradhata Y, van der Werf TS. Diagnosis of 
 tuberculosis through breath test: A systematic review. EBioMedicine. 2019a Aug 1;46:202-
 14. 
Saktiawati AM, Subronto YW, Stienstra Y, Supit F, van der Werf TS. Sensitivity and specificity 
 of routine diagnostic work-up for tuberculosis in lung clinics in Yogyakarta, Indonesia: a 
 cohort study. BMC Public Health. 2019b Dec 1;19(1):363. 
Sakula A. Robert Koch: centenary of the discovery of the tubercle bacillus, 1882. Thorax. 1982 
 Apr 1;37(4):246-51. 
SaMal J. Health seeking behaviour among tuberculosis patients in India: a systematic review. 
 Journal of clinical and diagnostic research: JCDR. 2016 Oct;10(10):LE01. 
Sawadogo M, Ciza F, Nzeyimana SD, Shingiro A, Ndikumana T, Demeulenaere T, Khogali M, 
 Edginton M, Reid AJ, Kumar AM, Harries AD. Effect of increased ART-CPT uptake on 
 tuberculosis outcomes and associated factors, Burundi, 2009–2013. Public health action. 
 2015 Dec 21;5(4):214-6. 
Schluger NW. The pathogenesis of tuberculosis: the first one hundred (and twenty-three) years. 
 American journal of respiratory cell and molecular biology. 2005 Apr;32(4):251-6. 
Seid MA, Ayalew MB, Muche EA, Gebreyohannes EA, Abegaz TM. Drug-susceptible 
 tuberculosis treatment success and associated factors in Ethiopia from 2005 to 2017: a 
 systematic review and meta-analysis. BMJ open. 2018 Sep 1;8(9):e022111.  
Sunday O, Oladimeji O, Ebenezer F, Akintunde B, Abiola TO, Saliu A, Abiodun O. Treatment 
 outcome of tuberculosis patients registered at dots centre in ogbomoso, southwestern 
 Nigeria: a 4-year retrospective study. Tuberculosis research and treatment. 2014 Jan 
 1;2014. 
Suthar AB, Granich R, Mermin J, Van Rie A. Effect of cotrimoxazole on mortality in HIV-infected 
 adults on antiretroviral therapy: a systematic review and meta-analysis. Bulletin of the 
 World Health Organization. 2012; 90:128-38. 
Telisinghe L, Charalambous S, Topp SM, Herce ME, Hoffmann CJ, Barron P, Schouten EJ, Jahn 
 A, Zachariah R, Harries AD, Beyrer C. HIV and tuberculosis in prisons in sub-Saharan 
 Africa. The Lancet. 2016 Sep 17;388(10050):1215-27.  
Thwaites G. Section 8: Mycobacterial infections – tuberculosis. In Manson’s tropical infectious 
 diseases, editors: Farrar J, Hotez PJ, Junghanss T, Kang G, Lalloo D, White NJ. 23rd ed, 
 Elsevier 2014. 
Tilahun G, Gebre-Selassie S. Treatment outcomes of childhood tuberculosis in Addis Ababa: a 
 five-year retrospective analysis. BMC Public Health. 2016 Dec;16(1):1-0.  
64 
 
Tola A, Minshore KM, Ayele Y, Mekuria AN. Tuberculosis treatment outcomes and associated 
 factors among TB patients attending public hospitals in Harar town, Eastern Ethiopia: A 
 five-year retrospective study. Tuberculosis research and treatment. 2019 April 1;2019:1-
 11. 
Torrelles JB, Schlesinger LS. Integrating Lung Physiology, Immunology, and Tuberculosis. 
 Trends Microbiol. 2017 Aug;25(8):688-697.  
Toman K. Identification of the sources of tuberculosis infection in countries with a low incidence 
 of tuberculosis. Bulletin of the International Union Against Tuberculosis, 1974, 49:208–
 221. 
Toman, K. How does pulmonary tuberculosis develop and how can it be detected at an early 
 stage? In: Frieden, T. 2nd ed. Toman’s tuberculosis case detection, treatment, and 
 monitoring: questions and answers, WHO; 2004, 64-71 
Trajman A, Schwartzman K. Improving diagnosis of tuberculosis in children. The Lancet. 
 Infectious diseases. 2021 Mar;21(3):302-3. 
Uddin MK, Chowdhury MR, Ahmed S, Rahman MT, Khatun R, van Leth F, Banu S. Comparison 
 of direct versus concentrated smear microscopy in detection of pulmonary tuberculosis. 
 BMC Res Notes. 2013 Jul 25;6:291.  
UNAID. Global tuberculosis report: living with HIV but dying from TB. 2017 Nov. 03. 
 https://www.unaids.org/en/resources/presscentre/featurestories/2017/november/2017110
 3_tbhttps://www.unaids.org/en/resources/presscentre/featurestories/2017/november/2017
 1103_tb [Accessed 06.07.2021] 
UNAIDS. Global HIV and AIDS statistics – fact sheet. 2021 
 https://www.unaids.org/en/resources/fact-sheet [Accessed: 06.07.2021]. 
Vanguard. 302,096 tuberculosis cases undetected in Nigeria – NTBLCP. 2018 Mar 15. 
 https://www.vanguardngr.com/2018/03/302096-tuberculosis-cases-undetected-nigeria-
 ntblcp/  
Van Rie A, Mellet K, John MA, Scott L, Page-Shipp L, Dansey H, Victor T, Warren R. False-
 positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications. 
 Int J Tuberc Lung Dis. 2012 Feb;16(2):206-8.  
Van Soolingen D, Hoogenboezem T, De Haas PE, Hermans PW, Koedam MA, Teppema KS, 
 Brennan PJ, Besra GS, Portaels F, Top J, Schouls LM. A novel pathogenic taxon of the 
 Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate 
 from Africa. International Journal of Systematic and Evolutionary Microbiology. 1997 
 Oct 1;47(4):1236-45. 
Villemin JA. ´Etudes sur la tuberculose. Paris: Bailli`ere; 1868. 
Vinuesa V, Borrás R, Briones ML, Clari MÁ, Cresencio V, Giménez E, Muñoz C, Oltra R, 
 Servera E, Scheelje T, Tornero C. Performance of a highly sensitive Mycobacterium 
65 
 
 tuberculosis complex real-time PCR assay for diagnosis of pulmonary tuberculosis in a 
 low-prevalence setting: a prospective intervention study. Journal of clinical 
 microbiology. 2018 May 1;56(5). 
World Health Organization (WHO). New laboratory diagnostic tools for tuberculosis control. 
 Geneva. 2008a. https://www.who.int/tdr/publications/documents/diagnostic-tool-tb.pdf 
WHO. Policy Statement. Molecular Line Probe Assay for Rapid Screening of Patients at Risk of 
 Multidrug-resistant (MDR) TB. Geneva, 2008b. 
 https://www.who.int/tb/features_archive/policy_statement.pdf?ua=1 
WHO 2009. Global Tuberculosis control: epidemiología, strategy, financing. Geneva: World 
 Health; 2009. 
WHO. Tuberculosis: IGRA TB tests policy statement 2011. Geneva, Switzerland, 2011a 
WHO. Policy Statement Automated real-time nucleic acid amplification technology for rapid and 
 simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. 
 Geneva, 2011b. 
 http://www.stoptb.org/wg/new_diagnostics/assets/documents/WHOpolicy_AutomatedN
 AAT.pdf 
WHO. Rapid Implementation of the Xpert MTB/RIF diagnostic test. Geneva WHO 2011c. 
 http://www.stoptb.org/wg/gli/assets/documents/xpert%20rapid%20implementation%20do
 cument.pdf 
WHO. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and 
 other stakeholders. WHO/HTM/ TB/2012.1. Geneva, Switzerland; 2012. 
WHO. Definitions and reporting framework for tuberculosis – 2013 Revision 
 (WHO/HTM/TB/2013.2). Geneva, Switzerland; 2013. [Accessed 20.08.2019]. 
WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-
 resistant tuberculosis. World Health Organization; 2014a. 
WHO. Xpert MTB/RIF Implementation Manual: Technical and Operational ‘How-To’; Practical 
 Considerations. Geneva; 2014b. Available from: 
 https://www.ncbi.nlm.nih.gov/books/NBK254326/[Accessed 04.05.2021]. 
WHO. The End TB strategy. Geneva. Switzerland . 2014c. 
 https://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1 [Accessed  01.02.2020] 
WHO. 2015. Implementing tuberculosis diagnostics. Policy framework.  




WHO. Tuberculosis diagnostics: automated real-time DNA amplification test for rapid and 
 simultaneous detection of TB and rifampicin resistance - Xpert MTB/RIF assay. Geneva. 
 2016b https://www.who.int/tb/publications/factsheet_xpert.pdf 
WHO. Q & A: What is TB? How does it spread? How is it treated. 2018 Jan 18. 
 https://www.who.int/news-room/q-a-detail/what-is-tb-how-is-it-treated [Accessed 
 26.10.2020] 
WHO. Global tuberculosis report 2019. Geneva, Switzerland, 2019a. 
WHO. Guidance for tuberculosis programme managers. Geneva, Switzerland, 2019b. 
 https://www.who.int/healthinfo/FacilityAnalysisGuide_TB.pdf?ua=1 [Accessed 
 22.06.2020] 
WHO. Information note: TB diagnostics and laboratory services. Geneva. 2020a. 
 https://www.who.int/tb/dots/lab.pdf [Accessed 20.11.2020]. 
WHO - Eastern Mediterranean Regional Office (WHO-EMRO) Cairo: STOP TB: TB Situation 
 in Region—Country Profile Pakistan. 2008. http://www.emro.who.int/index.html   
Young LR. Human tuberculosis epidemiology and agricultural transmission risks. Virginia 


















Appendix 1:  Treatment outcomes of new smear positive PTB registered at UPTH, Port Harcourt, 
Nigeria (2014 – 2019) 
Treatment 
outcomes   Years    Total Percentage 
 2014 2015 2016 2017 2018 2019   
Cured 13 30 26 14 1 1 76 48.1 
Completed 9 17 7 2 0 0 27 17.1 
Failed 1 4 1 0 0 0 5 3.2 
Died 1 8 6 1 0 0 13 8.2 
Lost 4 8 4 2 1 1 18 11.4 
Transferred 4 7 4 4 0 0 17 10.8 
Not evaluated 0 0 1 1 0 0 2 1.3 
Total  32 74 49 24 2 2 158 100 
Percentage  20.3 46.8 31.0 15.2 1.3 1.3 100  
 
 
Appendix 2:  Treatment outcomes of new smear negative PTB registered at UPTH, Port Harcourt, 
Nigeria (2014 – 2019) 
Treatment 
outcomes   Years    Total Percentage 
 2014 2015 2016 2017 2018 2019   
Cured 5 3 10 24 28 37 107 47.3 
Completed 15 9 10 2 8 6 50 22.1 
Failed 0 0 0 0 0 4 4 1.8 
Died 2 9 3 0 2 2 18 8.0 
Lost 4 4 1 2 2 4 17 7.5 
Transferred 3 4 0 3 5 0 15 6.6 
Not evaluated 0 1 1 1 1 11 15 6.6 
Total  29 30 25 32 46 64 226 100 












Appendix 3: The distribution of treatment outcomes across predictor variables 
Variable Cured Completed Failed Died Lost Transferred 
Not 
evaluated 
 n(%) n(%) n(%) n(%) n(%) n(%) n(%) 
Age (years) 
0 - 14   16(7.1) 77(37.0) 1(6.7) 17(15.5) 43(39.5) 30(33.3) 11(19.0) 
15 - 24  50(22.1) 28(13.5) 2(13.3) 8(7.3) 11(10.1) 8(8.9) 8(13.8) 
25 - 34 54(23.9) 41(19.7) 1(6.7) 15(13.6) 14(12.8) 13(14.4) 13(22.4) 
35 - 44 49(21.7) 40(19.2) 3(20.0) 25(22.7) 21(19.3) 23(25.6) 11(19.0) 
45 - 54 34(15.0) 14(6.7) 6(40.0) 27(24.6) 12(11.0) 5(5.6) 9(15.5) 
≥55 23(10.2) 8(3.9) 2(13.3) 18(16.4) 8(7.3) 11(12.2) 6(10.3) 
Total 226(100) 208(100) 15(100) 110(100) 109(100) 90(100) 58(100) 
Sex 
Male 112(49.6) 107(51.4) 8(53.3) 69(62.7) 62(56.9) 56(62.2) 29(50.0) 
Female 114(50.4) 101(48.6) 7(46.7) 41(37.3) 47(43.1) 34(37.8) 29(50.0) 
                                                                 
        Total 226(100) 208(100) 15(100) 110(100) 109(100) 90(100) 58(100) 
Type of TB 
PTB 220(97.3) 155(74.5) 11(73.3) 90(81.8) 92(84.4) 63(70.0) 47(81.0) 
EPTB 5(2.2) 43(20.7) 3(20.0) 15(13.6) 15(13.8) 21(23.3) 11(19.0) 
Missing 1(0.4) 10(4.8) 1(6.7) 5(4.5) 2(1.8) 6(6.7) 0(0.0) 
Total 226(100) 208(100) 15(100) 110(100) 109(100) 90(100) 58(100) 
Type of patient 
New 198(87.6) 187(89.9) 15(100.0) 98(89.1) 100(91.7) 86(95.6) 52(89.7) 
Retreatment relapse 12(5.3) 8(3.8) 0(0.0) 3(2.7) 2(1.8) 2(2.2) 1(1.7) 
Retreatment after failure 6(2.7) 2(1.0) 0(0.0) 2(1.8) 0(0.0) 0(0.0) 1(1.7) 
Retreatment after loss to follow-
up 6(2.7) 4(1.9) 0(0.0) 3(2.7) 2(1.8) 1(1.1) 1(1.7) 
Retreatment, others 3(1.3) 4(1.9) 0(0.0) 2(1.8) 5(4.6) 0(0.0) 2(3.4) 
Missing 1(0.4) 3(1.4) 0(0.0) 2(1.8) 0(0.0) 1(1.1) 1(1.7) 
Total 226(100) 208(100) 15(100) 110(100) 109(100) 90(100) 58(100) 
HIV status 
Positive 58(25.7) 71(34.1) 1(6.7) 72(65.5) 45(41.3) 33(36.7) 25(43.1) 
Negative 167(73.9) 136(65.4) 14(93.3) 36(32.7) 55(50.5) 56(62.2) 32(55.2) 
Unknown 1(0.4) 1(0.5) 0(0.0) 2(1.8) 9(8.3) 1(1.1) 1(1.7) 
Total 226(100) 208(100) 15(100) 110(100) 109(100) 90(100) 58(100) 
HIV care & support 
On ART 57(25.2) 72(34.6) 1(6.7) 66(60.0) 41(37.6) 33(36.7) 21(36.2) 
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Not on ART 169(74.8) 136(65.4) 14(93.3) 44(40.0) 68(62.4) 57(63.3) 37(63.8) 
                                                        
Total 226(100) 208(100) 15(100) 110(100) 109(100) 90(100) 58(100) 
On CPT 57(25.2) 70(33.7) 1(6.7) 64(58.2) 41(37.6) 32(35.6) 21(36.2) 
Not on CPT 169(74.8) 138(66.3) 14(93.3) 46(41.8) 68(62.4) 58(64.4) 37(63.8) 
                                                        
        Total 226(100) 208(100) 15(100) 110(100) 109(100) 90(100) 58(100) 
Regimen 
Standard(2HRZE/4HR) 220(97.3) 186(89.4) 12(80.0) 100(90.9) 97(89.0) 84(93.3) 53(91.4) 
Retreatment(2SHRZE/1HRZE/3HRE 6(2.7) 22(10.6) 3(20.0) 10(9.1) 12(11.0) 6(6.7) 4(6.9) 
Missing 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 1(1.7) 
                                                      
        Total 226(100) 208(100) 15(100) 110(100) 109(100) 90(100) 58(100) 
Diagnostic method 
Smear microscopy 122(54.0) 83(39.9) 6(40.0) 30(27.3) 33(30.3) 27(30.0) 5(8.6) 
Xpert MTB/RIF 89(39.4) 19(9.1) 7(46.7) 27(24.5) 20(18.3) 20(22.2) 25(43.1) 
Others 15(6.6) 103(49.5) 2(13.3) 47(42.7) 52(47.7) 41(45.6) 22(37.9) 
Missing 0(0.0) 3(1.4) 0(0.0) 6(5.5) 4(3.7) 2(2.2) 6(10.3) 
                                                       
                                      Total 226(100) 208(100) 15(100) 110(100) 109(100) 90(100) 58(100) 
Smear Microscopy result 
Negative 128(56.6) 71(34.1) 5(33.3) 23(20.9) 25(22.9) 21(23.3) 19(32.8) 
Positive: 1+ 53(23.5) 17(8.2) 1(6.7) 6(5.5) 11(10.1) 12(13.3) 1(1.7) 
Positive: 2+ 11(4.9) 9(4.3) 3(20.0) 3(2.7) 5(4.6) 5(5.6) 0(0.0) 
Positive: 3+ 11(4.9) 5(2.4) 1(6.7) 3(2.7) 1(0.9) 1(1.1) 0(0.0) 
Scanty 10(4.4) 4(1.9) 1(6.7) 4(3.6) 3(2.8) 1(1.1) 1(1.7) 
Missing 13(5.8) 102(49.0) 4(26.7) 71(64.5) 64(58.7) 50(55.6) 37(63.8) 
                                                       
        Total 226(100) 208(100) 15(100) 110(100) 109(100) 90(100) 58(100) 
Xpert MTB/RIF result 
Negative 25(11.1) 34(16.3) 2(13.3) 9(8.2) 5(4.6) 6(6.7) 13(22.4) 
MTB 133(58.8) 24(11.5) 9(60.0) 29(26.4) 25(22.9) 24(26.7) 22(37.9) 
Resistant 0(0.0) 0(0.0) 1(6.7) 1(0.9) 0(0.0) 1(1.1) 1(1.7) 
Missing 68(30.1) 150(72.1) 3(20.0) 71(64.5) 79(72.5) 59(65.6) 22(37.9) 
                                                      
        Total 226(100) 208(100) 15(100) 110(100) 109(100) 90(100) 58(100) 
Weight (Kg) 
0-14 7(3.1) 48(23.2) 1(6.7) 12(10.9) 35(33.0) 23(25.8) 8(14.6) 
15-24 6(2.7) 21(10.1) 0(0.0) 6(5.5) 3(2.8) 2(2.3) 2(3.6) 
25-34 6(2.7) 6(2.9) 0(0.0) 4(3.6) 5(4.7) 5(5.6) 3(5.5) 
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35-44 32(14.2) 16(7.7) 3(20.0) 16(14.6) 17(16.0) 11(12.4) 5(9.1) 
45-54 78(34.7) 43(20.8) 8(53.3) 35(31.8) 19(17.9) 23(25.8) 10(18.2) 
55-64 62(27.6) 46(22.2) 1(6.7) 29(26.4) 19(17.9) 14(15.7) 20(36.4) 
65-74 25(11.1) 20(9.7) 2(13.3) 6(5.5) 5(4.7) 9(10.1) 6(10.9) 
≥75 9(4.0) 7(3.4) 0(0.0) 2(1.8) 3(2.8) 2(2.3) 1(1.8) 
                                                        




Appendix 4: Comparison of sex, type of patients, type of TB, and 
HIV status of registered TB patients in UPTH, Nigeria based on their 
treatment success and unsuccessful outcomes (2014 – 2019)   





 2014     
Sex Male 43.8 57.1 2.28 0.1 
 Female 56.3 42.9 
      
 2015     
 Male 51.6 57.0 0.55 0.5 
 Female 48.4 43.0 
      
 2016     
 Male 48.1    57.1 0.79 0.4 
 Female 51.9 42.9 
      
 2017     
 Male 56.1 58.8 0.90 0.8 
 Female 43.9 41.2 
      
 2018     
 Male 53.7 71.8 3.36 0.07 
 Female 46.3 28.2 
      
 2019     
 Male 49.2 65.1 2.65 0.1 
 Female 50.8 34.9 
      
                        
Total 
Male 52.9 47.1 7.08 0.01* 
                   Female 62.5 37.5   
 2014     
Type of 
patient 
New 85.9 90.5 1.31 0.6 
 Retreatment 12.5 9.5 
      
 2015     
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 New 91.6 93.5 0.31 0.9 
 Retreatment 7.4 5.4 
      
 2016     
 New 87.0 82.9 2.28 0.4 
 Retreatment 13.0 14.3   
      
 2017     
 New 83.3 94.1 3.61 0.2 
 Retreatment 13.6 5.9   
      
 2018     
 New 91.0 92.3 0.05 1.0 
 Retreatment 9.0 7.7   
      
 2019     
 New 92.3 97.7 4.89 0.07 
 Retreatment 7.7 0.0   
      
                 
Total 
New   56.3 43.7 2.95 0.09 
 Retreatment 67.2 32.8 
 2014     
Type of TB PTB 92.2 77.8 3.74 0.05* 
 EPTB 7.8 19.0   
      
 2015     
 PTB 80.5 71.0 2.11 0.2 
 EPTB 9.5 16.1   
      
 2016     
 PTB 5.7 94.3 0.37 0.5 
 EPTB 9.1 22.2   
      
 2017     
 PTB 83.3 78.4 0.45 0.5 
 EPTB 16.7 21.6   
      
 2018     
 PTB 82.1 74.4 1.23 0.3 
 EPTB  16.4 25.6   
      
 2019     
 PTB   92.3 90.7 0.88 0.8 
 EPTB 7.7 9.3   
      
                 
Total 
PTB 59.4 40.6 5.51 0.02* 
 EPTB 47.1 52.9   
 2014     
HIV status HIV + 43.8 53.5 0.95 0.3 
 HIV - 56.3 47.5   
      
72 
 
 2015     
 HIV + 31.9 41.4 1.75 0.2 
 HIV - 68.1 58.6   
      
 2016     
 HIV + 28.6 77.1 23.1 0.00* 
 HIV - 71.4 22.9   
      
 2017     
 HIV + 28.8 46.0 3.65 0.06 
 HIV - 71.2 54.0   
      
 2018     
 HIV + 27.3 41.0 2.12 0.2 
 HIV - 72.7 59.0   
      
 2019     
 HIV + 18.5 42.9 7.53 0.01* 
 HIV - 81.5 57.1   
      
 HIV + 46.1 53.9 26.5 0.00* 
Total    
 HIV - 65.3 34.7 
TSR = Treatment success rate, UTO = Unsuccessful treatment outcome, X2 = Chi-
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